Search

Your search keyword '"Roks G."' showing total 118 results
Start Over Author "Roks G." Language english
118 results on '"Roks G."'

2. Variation in Structure and Process of Care in Traumatic Brain Injury: Provider Profiles of European Neurotrauma Centers Participating in the CENTER-TBI Study

Author

Cnossen M. C., Polinder S., Lingsma H. F., Maas A. I. R., Menon D., Steyerberg E. W., Adams H., Alessandro M., Allanson J., Amrein K., Andaluz N., Andelic N., Andrea N., Andreassen L., Anke A., Antoni A., Ardon H., Audibert G., Auslands K., Azouvi P., Baciu C., Bacon A., Badenes R., Baglin T., Bartels R., Barzo P., Bauerfeind U., Beer R., Belda F. J., Bellander B. -M., Belli A., Bellier R., Benali H., Benard T., Berardino M., Beretta L., Beynon C., Bilotta F., Binder H., Biqiri E., Blaabjerg M., Borgen L. S., Bouzat P., Bragge P., Brazinova A., Brehar F., Brorsson C., Buki A., Bullinger M., Buckova V., Calappi E., Cameron P., Carbayo L. G., Carise E., Carpenter C., Castano-Leon A. M., Causin F., Chevallard G., Chieregato A., Citerio G., Coburn M. C., Coles J., Cooper J. D., Correia M., Covic A., Curry N., Czeiter E., Czosnyka M., Dahyot-Fizelier C., Damas F., Damas P., Dawes H., De Keyser V., Della Corte F., Depreitere B., Ding S., Dippel D., Dizdarevic K., Duliere G. -L., Dzeko A., Eapen G., Engemann H., Ercole A., Esser P., Ezer E., Fabricius M., Feigin V. L., Feng J., Foks K., Fossi F., Francony G., Frantzen J., Freo U., Frisvold S., Furmanov A., Gagliardo P., Galanaud D., Gao G., Geleijns K., Ghuysen A., Giraud B., Glocker B., Gomez P. A., Grossi F., Gruen R. L., Gupta D., Haagsma J. A., Hadzic E., Haitsma I., Hartings J. A., Helbok R., Helseth E., Hertle D., Hill S., Hoedemaekers A., Hoefer S., Hutchinson P. J., Haberg A. K., Jacobs B., Janciak I., Janssens K., Jiang J., Jones K., Kalala J. -P., Kamnitsas K., Karan M., Karau J., Katila A., Kaukonen M., Keeling D., Kerforne T., Ketharanathan N., Kettunen J., Kivisaari R., Kolias A. G., Kolumban B., Kompanje E., Kondziella D., Koskinen L. -O., Kovacs N., Kalovits F., Lagares A., Lanyon L., Laureys S., Lauritzen M., Lecky F., Ledig C., Lefering R., Legrand V., Lei J., Levi L., Lightfoot R., Lingsma H., Loeckx D., Lozano A., Luddington R., Luijten-Arts C., MacDonald S., MacFayden C., Maegele M., Majdan M., Major S., Manara A., Manhes P., Manley G., Martin D., Martino C., Maruenda A., Marechal H., Mastelova D., Mattern J., McMahon C., Melegh B., Menovsky T., Morganti-Kossmann C., Mulazzi D., Mutschler M., Muhlan H., Negru A., Nelson D., Neugebauer E., Newcombe V., Noirhomme Q., Nyiradi J., Oddo M., Oldenbeuving A., Oresic M., Ortolano F., Palotie A., Parizel P. M., Patruno A., Payen J. -F., Perera N., Perlbarg V., Persona P., Peul W., Pichon N., Piilgaard H., Piippo A., Pili F. S., Pirinen M., Ples H., Pomposo I., Psota M., Pullens P., Puybasset L., Ragauskas A., Raj R., Rambadagalla M., Rehorcikova V., Rhodes J., Richardson S., Ripatti S., Rocka S., Rodier N., Roe C., Roise O., Roks G., Romegoux P., Rosand J., Rosenfeld J., Rosenlund C., Rosenthal G., Rossaint R., Rossi S., Rostalski T., Rueckert D. L., Ruiz De Arcaute F., Rusnak M., Sacchi M., Sahakian B., Sahuquillo J., Sakowitz O., Sala F., Sanchez-Pena P., Sanchez-Porras R., Sandor J., Santos E., Sasse N., Sasu L., Savo D., Schipper I., Schlosser B., Schmidt S., Schneider A., Schoechl H., Schoonman G., Schou R. F., Schwendenwein E., Scholl M., Sir O., Skandsen T., Smakman L., Smeets D., Smielewski P., Sorinola A., Stamatakis E. L., Stanworth S., Stegemann K., Steinbuchel N., Stevens R., Stewart W., Stocchetti N., Sundstrom N., Synnot A., Szabo J., Soderberg J., Taccone F. S., Tamas V., Tanskanen P., Tascu A., Taylor M. S., Te Ao B., Tenovuo O., Teodorani G., Theadom A., Thomas M., Tibboel D., Tolias C., Tshibanda J. -F. L., Tudora C. M., Vajkoczy P., Valeinis E., Van Hecke W., Van Praag D., Van Roost D., Van Vlierberghe E., Vande Vyvere T., Vanhaudenhuyse A., Vargiolu A., Vega E., Verheyden J., Vespa P. M., Vik A., Vilcinis R., Vizzino G., Vleggeert-Lankamp C., Volovici V., Vulekovic P., Vamos Z., Wade D., Wang K. K. W., Wang L., Wildschut E., Williams G., Willumsen L., Wilson A., Wilson L., Winkler M. K. L., Ylen P., Younsi A., Zaaroor M., Zhang Z., Zheng Z., Zumbo F., De Lange S., De Ruiter G. C. W., Den Boogert H., Van Dijck J., Van Essen T. A., Van Heugten C., Van Der Jagt M., Van Der Naalt J., CENTER-Tbi Invest Participants, Cnossen, M, Polinder, S, Lingsma, H, Maas, A, Menon, D, Steyerberg, E, Adams, H, Alessandro, M, Allanson, J, Amrein, K, Andaluz, N, Andelic, N, Andrea, N, Andreassen, L, Anke, A, Antoni, A, Ardon, H, Audibert, G, Auslands, K, Azouvi, P, Baciu, C, Bacon, A, Badenes, R, Baglin, T, Bartels, R, Barzo, P, Bauerfeind, U, Beer, R, Belda, F, Bellander, B, Belli, A, Bellier, R, Benali, H, Benard, T, Berardino, M, Beretta, L, Beynon, C, Bilotta, F, Binder, H, Biqiri, E, Blaabjerg, M, Borgen, L, Bouzat, P, Bragge, P, Brazinova, A, Brehar, F, Brorsson, C, Buki, A, Bullinger, M, Buckova, V, Calappi, E, Cameron, P, Carbayo, L, Carise, E, Carpenter, C, Castano-Leon, A, Causin, F, Chevallard, G, Chieregato, A, Citerio, G, Coburn, M, Coles, J, Cooper, J, Correia, M, Covic, A, Curry, N, Czeiter, E, Czosnyka, M, Dahyot-Fizelier, C, Damas, F, Damas, P, Dawes, H, De Keyser, V, Della Corte, F, Depreitere, B, Ding, S, Dippel, D, Dizdarevic, K, Duliere, G, Dzeko, A, Eapen, G, Engemann, H, Ercole, A, Esser, P, Ezer, E, Fabricius, M, Feigin, V, Feng, J, Foks, K, Fossi, F, Francony, G, Frantzen, J, Freo, U, Frisvold, S, Furmanov, A, Gagliardo, P, Galanaud, D, Gao, G, Geleijns, K, Ghuysen, A, Giraud, B, Glocker, B, Gomez, P, Grossi, F, Gruen, R, Gupta, D, Haagsma, J, Hadzic, E, Haitsma, I, Hartings, J, Helbok, R, Helseth, E, Hertle, D, Hill, S, Hoedemaekers, A, Hoefer, S, Hutchinson, P, Haberg, A, Jacobs, B, Janciak, I, Janssens, K, Jiang, J, Jones, K, Kalala, J, Kamnitsas, K, Karan, M, Karau, J, Katila, A, Kaukonen, M, Keeling, D, Kerforne, T, Ketharanathan, N, Kettunen, J, Kivisaari, R, Kolias, A, Kolumban, B, Kompanje, E, Kondziella, D, Koskinen, L, Kovacs, N, Kalovits, F, Lagares, A, Lanyon, L, Laureys, S, Lauritzen, M, Lecky, F, Ledig, C, Lefering, R, Legrand, V, Lei, J, Levi, L, Lightfoot, R, Loeckx, D, Lozano, A, Luddington, R, Luijten-Arts, C, Macdonald, S, Macfayden, C, Maegele, M, Majdan, M, Major, S, Manara, A, Manhes, P, Manley, G, Martin, D, Martino, C, Maruenda, A, Marechal, H, Mastelova, D, Mattern, J, Mcmahon, C, Melegh, B, Menovsky, T, Morganti-Kossmann, C, Mulazzi, D, Mutschler, M, Muhlan, H, Negru, A, Nelson, D, Neugebauer, E, Newcombe, V, Noirhomme, Q, Nyiradi, J, Oddo, M, Oldenbeuving, A, Oresic, M, Ortolano, F, Palotie, A, Parizel, P, Patruno, A, Payen, J, Perera, N, Perlbarg, V, Persona, P, Peul, W, Pichon, N, Piilgaard, H, Piippo, A, Pili, F, Pirinen, M, Ples, H, Pomposo, I, Psota, M, Pullens, P, Puybasset, L, Ragauskas, A, Raj, R, Rambadagalla, M, Rehorcikova, V, Rhodes, J, Richardson, S, Ripatti, S, Rocka, S, Rodier, N, Roe, C, Roise, O, Roks, G, Romegoux, P, Rosand, J, Rosenfeld, J, Rosenlund, C, Rosenthal, G, Rossaint, R, Rossi, S, Rostalski, T, Rueckert, D, Ruiz De Arcaute, F, Rusnak, M, Sacchi, M, Sahakian, B, Sahuquillo, J, Sakowitz, O, Sala, F, Sanchez-Pena, P, Sanchez-Porras, R, Sandor, J, Santos, E, Sasse, N, Sasu, L, Savo, D, Schipper, I, Schlosser, B, Schmidt, S, Schneider, A, Schoechl, H, Schoonman, G, Schou, R, Schwendenwein, E, Scholl, M, Sir, O, Skandsen, T, Smakman, L, Smeets, D, Smielewski, P, Sorinola, A, Stamatakis, E, Stanworth, S, Stegemann, K, Steinbuchel, N, Stevens, R, Stewart, W, Stocchetti, N, Sundstrom, N, Synnot, A, Szabo, J, Soderberg, J, Taccone, F, Tamas, V, Tanskanen, P, Tascu, A, Taylor, M, Te Ao, B, Tenovuo, O, Teodorani, G, Theadom, A, Thomas, M, Tibboel, D, Tolias, C, Tshibanda, J, Tudora, C, Vajkoczy, P, Valeinis, E, Van Hecke, W, Van Praag, D, Van Roost, D, Van Vlierberghe, E, Vande Vyvere, T, Vanhaudenhuyse, A, Vargiolu, A, Vega, E, Verheyden, J, Vespa, P, Vik, A, Vilcinis, R, Vizzino, G, Vleggeert-Lankamp, C, Volovici, V, Vulekovic, P, Vamos, Z, Wade, D, Wang, K, Wang, L, Wildschut, E, Williams, G, Willumsen, L, Wilson, A, Wilson, L, Winkler, M, Ylen, P, Younsi, A, Zaaroor, M, Zhang, Z, Zheng, Z, Zumbo, F, De Lange, S, De Ruiter, G, Den Boogert, H, Van Dijck, J, Van Essen, T, Van Heugten, C, Van Der Jagt, M, Van Der Naalt, J, Cnossen, M. C., Polinder, S., Lingsma, H. F., Maas, A. I. R., Menon, D., Steyerberg, E. W., Adams, H., Alessandro, M., Allanson, J., Amrein, K., Andaluz, N., Andelic, N., Andrea, N., Andreassen, L., Anke, A., Antoni, A., Ardon, H., Audibert, G., Auslands, K., Azouvi, P., Baciu, C., Bacon, A., Badenes, R., Baglin, T., Bartels, R., Barzo, P., Bauerfeind, U., Beer, R., Belda, F. J., Bellander, B. -M., Belli, A., Bellier, R., Benali, H., Benard, T., Berardino, M., Beretta, L., Beynon, C., Bilotta, F., Binder, H., Biqiri, E., Blaabjerg, M., Borgen, L. S., Bouzat, P., Bragge, P., Brazinova, A., Brehar, F., Brorsson, C., Buki, A., Bullinger, M., Buckova, V., Calappi, E., Cameron, P., Carbayo, L. G., Carise, E., Carpenter, C., Castano-Leon, A. M., Causin, F., Chevallard, G., Chieregato, A., Citerio, G., Coburn, M. C., Coles, J., Cooper, J. D., Correia, M., Covic, A., Curry, N., Czeiter, E., Czosnyka, M., Dahyot-Fizelier, C., Damas, F., Damas, P., Dawes, H., De Keyser, V., Della Corte, F., Depreitere, B., Ding, S., Dippel, D., Dizdarevic, K., Duliere, G. -L., Dzeko, A., Eapen, G., Engemann, H., Ercole, A., Esser, P., Ezer, E., Fabricius, M., Feigin, V. L., Feng, J., Foks, K., Fossi, F., Francony, G., Frantzen, J., Freo, U., Frisvold, S., Furmanov, A., Gagliardo, P., Galanaud, D., Gao, G., Geleijns, K., Ghuysen, A., Giraud, B., Glocker, B., Gomez, P. A., Grossi, F., Gruen, R. L., Gupta, D., Haagsma, J. A., Hadzic, E., Haitsma, I., Hartings, J. A., Helbok, R., Helseth, E., Hertle, D., Hill, S., Hoedemaekers, A., Hoefer, S., Hutchinson, P. J., Haberg, A. K., Jacobs, B., Janciak, I., Janssens, K., Jiang, J., Jones, K., Kalala, J. -P., Kamnitsas, K., Karan, M., Karau, J., Katila, A., Kaukonen, M., Keeling, D., Kerforne, T., Ketharanathan, N., Kettunen, J., Kivisaari, R., Kolias, A. G., Kolumban, B., Kompanje, E., Kondziella, D., Koskinen, L. -O., Kovacs, N., Kalovits, F., Lagares, A., Lanyon, L., Laureys, S., Lauritzen, M., Lecky, F., Ledig, C., Lefering, R., Legrand, V., Lei, J., Levi, L., Lightfoot, R., Lingsma, H., Loeckx, D., Lozano, A., Luddington, R., Luijten-Arts, C., Macdonald, S., Macfayden, C., Maegele, M., Majdan, M., Major, S., Manara, A., Manhes, P., Manley, G., Martin, D., Martino, C., Maruenda, A., Marechal, H., Mastelova, D., Mattern, J., Mcmahon, C., Melegh, B., Menovsky, T., Morganti-Kossmann, C., Mulazzi, D., Mutschler, M., Muhlan, H., Negru, A., Nelson, D., Neugebauer, E., Newcombe, V., Noirhomme, Q., Nyiradi, J., Oddo, M., Oldenbeuving, A., Oresic, M., Ortolano, F., Palotie, A., Parizel, P. M., Patruno, A., Payen, J. -F., Perera, N., Perlbarg, V., Persona, P., Peul, W., Pichon, N., Piilgaard, H., Piippo, A., Pili, F. S., Pirinen, M., Ples, H., Pomposo, I., Psota, M., Pullens, P., Puybasset, L., Ragauskas, A., Raj, R., Rambadagalla, M., Rehorcikova, V., Rhodes, J., Richardson, S., Ripatti, S., Rocka, S., Rodier, N., Roe, C., Roise, O., Roks, G., Romegoux, P., Rosand, J., Rosenfeld, J., Rosenlund, C., Rosenthal, G., Rossaint, R., Rossi, S., Rostalski, T., Rueckert, D. L., Ruiz De Arcaute, F., Rusnak, M., Sacchi, M., Sahakian, B., Sahuquillo, J., Sakowitz, O., Sala, F., Sanchez-Pena, P., Sanchez-Porras, R., Sandor, J., Santos, E., Sasse, N., Sasu, L., Savo, D., Schipper, I., Schlosser, B., Schmidt, S., Schneider, A., Schoechl, H., Schoonman, G., Schou, R. F., Schwendenwein, E., Scholl, M., Sir, O., Skandsen, T., Smakman, L., Smeets, D., Smielewski, P., Sorinola, A., Stamatakis, E. L., Stanworth, S., Stegemann, K., Steinbuchel, N., Stevens, R., Stewart, W., Stocchetti, N., Sundstrom, N., Synnot, A., Szabo, J., Soderberg, J., Taccone, F. S., Tamas, V., Tanskanen, P., Tascu, A., Taylor, M. S., Te Ao, B., Tenovuo, O., Teodorani, G., Theadom, A., Thomas, M., Tibboel, D., Tolias, C., Tshibanda, J. -F. L., Tudora, C. M., Vajkoczy, P., Valeinis, E., Van Hecke, W., Van Praag, D., Van Roost, D., Van Vlierberghe, E., Vande Vyvere, T., Vanhaudenhuyse, A., Vargiolu, A., Vega, E., Verheyden, J., Vespa, P. M., Vik, A., Vilcinis, R., Vizzino, G., Vleggeert-Lankamp, C., Volovici, V., Vulekovic, P., Vamos, Z., Wade, D., Wang, K. K. W., Wang, L., Wildschut, E., Williams, G., Willumsen, L., Wilson, A., Wilson, L., Winkler, M. K. L., Ylen, P., Younsi, A., Zaaroor, M., Zhang, Z., Zheng, Z., Zumbo, F., De Lange, S., De Ruiter, G. C. W., Den Boogert, H., Van Dijck, J., Van Essen, T. A., Van Heugten, C., Van Der Jagt, M., Van Der Naalt, J., Commission of the European Communities, Molecular Neuroscience and Ageing Research (MOLAR), Menon, David [0000-0002-3228-9692], Apollo - University of Cambridge Repository, and Public Health

Subjects
Questionnaires, Comparative Effectiveness Research, Critical Care and Emergency Medicine, Medical Doctors, Neurologi, Health Care Providers, CENTER-TBI Investigators and Participants, lcsh:Medicine, Poison control, Occupational safety and health, Diagnostic Radiology, Geographical Locations, 0302 clinical medicine, Trauma Centers, Surveys and Questionnaires, Brain Injuries, Traumatic, Medicine and Health Sciences, Brain Damage, Longitudinal Studies, Prospective Studies, Israel, lcsh:Science, Tomography, Trauma Medicine, Multidisciplinary, Radiology and Imaging, traumatic brain injury, Trauma center, Hospitals, 3. Good health, Europe, Hospitalization, Professions, Intensive Care Units, Neurology, Research Design, Intracranial pressure monitoring, Medical emergency, Engineering sciences. Technology, Research Article, medicine.medical_specialty, Imaging Techniques, Traumatic brain injury, General Science & Technology, Concordance, Comparative effectiveness research, Neuroimaging, Research and Analysis Methods, 03 medical and health sciences, Diagnostic Medicine, Physicians, Injury prevention, MD Multidisciplinary, medicine, Humans, Treatment Guidelines, Survey Research, Health Care Policy, business.industry, lcsh:R, Biology and Life Sciences, 030208 emergency & critical care medicine, Length of Stay, medicine.disease, ta3124, Computed Axial Tomography, Health Care, Health Care Facilities, Family medicine, People and Places, lcsh:Q, Population Groupings, business, 030217 neurology & neurosurgery, Neuroscience
Abstract

© 2016 Cnossen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.Introduction: The strength of evidence underpinning care and treatment recommendations in traumatic brain injury (TBI) is low. Comparative effectiveness research (CER) has been proposed as a framework to provide evidence for optimal care for TBI patients. The first step in CER is to map the existing variation. The aim of current study is to quantify variation in general structural and process characteristics among centers participating in the Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) study. Methods: We designed a set of 11 provider profiling questionnaires with 321 questions about various aspects of TBI care, chosen based on literature and expert opinion. After pilot testing, questionnaires were disseminated to 71 centers from 20 countries participating in the CENTER-TBI study. Reliability of questionnaires was estimated by calculating a concordance rate among 5% duplicate questions. Results: All 71 centers completed the questionnaires. Median concordance rate among duplicate questions was 0.85. The majority of centers were academic hospitals (n = 65, 92%), designated as a level I trauma center (n = 48, 68%) and situated in an urban location (n = 70, 99%). The availability of facilities for neuro-trauma care varied across centers; e.g. 40 (57%) had a dedicated neuro-intensive care unit (ICU), 36 (51%) had an in-hospital rehabilitation unit and the organization of the ICU was closed in 64% (n = 45) of the centers. In addition, we found wide variation in processes of care, such as the ICU admission policy and intracranial pressure monitoring policy among centers. Conclusion: Even among high-volume, specialized neurotrauma centers there is substantial variation in structures and processes of TBI care. This variation provides an opportunity to study effectiveness of specific aspects of TBI care and to identify best practices with CER approaches.

Published
2020
Full Text
View/download PDF

4. The use of EEG in the diagnosis of dementia with Lewy bodies

Author

Roks, G., Korf, E.S.C., Flier, W.M. van der, Scheltens, P., and Stam, C.J.

Subjects
Lewy body disease -- Diagnosis, Dementia -- Diagnosis, Electroencephalography -- Usage, Electroencephalography -- Research, Health, Psychology and mental health
Published
2008

5. Octapeptide repeat insertions in the prion protein gene and early onset dementia

Author

Croes, E.A., Theuns, J., Houwing-Duistermat, J.J., Dermaut, B., Sleegers, K., Roks, G., Van den Broeck, M., van Harten, B., van Swieten, J.C., Cruts, M., Van Broeckhoven, C., and van Duijn, C.M.

Subjects
Dementia -- Research, Dementia -- Genetic aspects, Prions -- Genetic aspects, Prions -- Research, Health, Psychology and mental health
Published
2004

7. Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research

Author

Maas, A, Menon, D, Adelson, P, Andelic, N, Bell, M, Belli, A, Bragge, P, Brazinova, A, Büki, A, Chesnut, R, CITERIO, GIUSEPPE, Coburn, M, Cooper, D, Crowder, A, Czeiter, E, Czosnyka, M, Diaz arrastia, R, Dreier, J, Duhaime, A, Ercole, A, Van Essen, T, Feigin, V, Gao, G, Giacino, J, Gonzalez lara, L, Gruen, R, Gupta, D, Hartings, J, Hill, S, Jiang, J, Ketharanathan, N, Kompanje, E, Lanyon, L, Laureys, S, Lecky, F, Levin, H, Lingsma, H, Maegele, M, Majdan, M, Manley, G, Marsteller, J, Mascia, L, Mcfadyen, C, Mondello, S, Newcombe, V, Palotie, A, Parizel, P, Peul, W, Piercy, J, Polinder, S, Puybasset, L, Rasmussen, T, Rossaint, R, Smielewski, P, Söderberg, J, Stanworth, S, Stein, M, Von Steinbüchel, N, Stewart, W, Steyerberg, E, Stocchetti, N, Synnot, A, Te Ao, B, Tenovuo, O, Theadom, A, Tibboel, D, Videtta, W, Wang, K, Williams, W, Wilson, L, Yaffe, K, Adams, H, Agnoletti, V, Allanson, J, Amrein, K, Andaluz, N, Anke, A, Antoni, A, Van As, A, Audibert, G, Azaševac, A, Azouvi, P, Azzolini, M, Baciu, C, Badenes, R, Barlow, K, Bartels, R, Bauerfeind, U, Beauchamp, M, Beer, D, Beer, R, Belda, F, Bellander, B, Bellier, R, Benali, H, Benard, T, Beqiri, V, Beretta, L, Bernard, F, Bertolini, G, Bilotta, F, Blaabjerg, M, Den Boogert, H, Boutis, K, Bouzat, P, Brooks, B, Brorsson, C, Bullinger, M, Burns, E, Calappi, E, Cameron, P, Carise, E, Castaño león, A, Causin, F, Chevallard, G, Chieregato, A, Christie, B, Cnossen, M, Coles, J, Collett, J, Della Corte, F, Craig, W, Csato, G, Csomos, A, Curry, N, Dahyot fizelier, C, Dawes, H, Dematteo, C, Depreitere, B, Dewey, D, Van Dijck, J, Đilvesi, Đ, Dippel, D, Dizdarevic, K, Donoghue, E, Duek, O, Dulière, G, Dzeko, A, Eapen, G, Emery, C, English, S, Esser, P, Ezer, E, Fabricius, M, Feng, J, Fergusson, D, Figaji, A, Fleming, J, Foks, K, Francony, G, Freedman, S, Freo, U, Frisvold, S, Gagnon, I, Galanaud, D, Gantner, D, Giraud, B, Glocker, B, Golubovic, J, Gómez López, P, Gordon, W, Gradisek, P, Gravel, J, Griesdale, D, Grossi, F, Haagsma, J, Håberg, A, Haitsma, I, Van Hecke, W, Helbok, R, Helseth, E, Van Heugten, C, Hoedemaekers, C, Höfer, S, Horton, L, Hui, J, Huijben, J, Hutchinson, P, Jacobs, B, Van Der Jagt, M, Jankowski, S, Janssens, K, Jelaca, B, Jones, K, Kamnitsas, K, Kaps, R, Karan, M, Katila, A, Kaukonen, K, De Keyser, V, Kivisaari, R, Kolias, A, Kolumbán, B, Kolundžija, K, Kondziella, D, Koskinen, L, Kovács, N, Kramer, A, Kutsogiannis, D, Kyprianou, T, Lagares, A, Lamontagne, F, Latini, R, Lauzier, F, Lazar, I, Ledig, C, Lefering, R, Legrand, V, Levi, L, Lightfoot, R, Lozano, A, Macdonald, S, Major, S, Manara, A, Manhes, P, Maréchal, H, Martino, C, Masala, A, Masson, S, Mattern, J, Mcfadyen, B, Mcmahon, C, Meade, M, Melegh, B, Menovsky, T, Moore, L, Morgado Correia, M, Morganti kossmann, M, Muehlan, H, Mukherjee, P, Murray, L, Van Der Naalt, J, Negru, A, Nelson, D, Nieboer, D, Noirhomme, Q, Nyirádi, J, Oddo, M, Okonkwo, D, Oldenbeuving, A, Ortolano, F, Osmond, M, Payen, J, Perlbarg, V, Persona, P, Pichon, N, Piippo karjalainen, A, Pili floury, S, Pirinen, M, Ple, H, Poca, M, Posti, J, Van Praag, D, Ptito, A, Radoi, A, Ragauskas, A, Raj, R, Real, R, Reed, N, Rhodes, J, Robertson, C, Rocka, S, Røe, C, Røise, O, Roks, G, Rosand, J, Rosenfeld, J, Rosenlund, C, Rosenthal, G, Rossi, S, Rueckert, D, De Ruiter, G, Sacchi, M, Sahakian, B, Sahuquillo, J, Sakowitz, O, Salvato, G, Sánchez porras, R, Sándor, J, Sangha, G, Schäfer, N, Schmidt, S, Schneider, K, Schnyer, D, Schöhl, H, Schoonman, G, Schou, R, Sir, Ö, Skandsen, T, Smeets, D, Sorinola, A, Stamatakis, E, Stevanovic, A, Stevens, R, Sundström, N, Taccone, F, Takala, R, Tanskanen, P, Taylor, M, Telgmann, R, Temkin, N, Teodorani, G, Thomas, M, Tolias, C, Trapani, T, Turgeon, A, Vajkoczy, P, Valadka, A, Valeinis, E, Vallance, S, Vámos, Z, VARGIOLU, ALESSIA, Vega, E, Verheyden, J, Vik, A, Vilcinis, R, Vleggeert lankamp, C, Vogt, L, Volovici, V, Voormolen, D, Vulekovic, P, Vande Vyvere, T, Van Waesberghe, J, Wessels, L, Wildschut, E, Williams, G, Winkler, M, Wolf, S, Wood, G, Xirouchaki, N, Younsi, A, Zaaroor, M, Zelinkova, V, Zemek, R, Zumbo, F, Citerio, G, Vargiolu, A, Zumbo, F., Maas, Andrew I R, Menon, David K, Adelson, P David, Andelic, Nada, Bell, Michael J, Belli, Antonio, Bragge, Peter, Brazinova, Alexandra, Büki, Andrá, Chesnut, Randall M, Citerio, Giuseppe, Coburn, Mark, Cooper, D Jamie, Crowder, A Tamara, Czeiter, Endre, Czosnyka, Marek, Diaz-Arrastia, Ramon, Dreier, Jens P, Duhaime, Ann-Christine, Ercole, Ari, van Essen, Thomas A, Feigin, Valery L, Gao, Guoyi, Giacino, Joseph, Gonzalez-Lara, Laura E, Gruen, Russell L, Gupta, Deepak, Hartings, Jed A, Hill, Sean, Jiang, Ji-yao, Ketharanathan, Naomi, Kompanje, Erwin J O, Lanyon, Linda, Laureys, Steven, Lecky, Fiona, Levin, Harvey, Lingsma, Hester F, Maegele, Marc, Majdan, Marek, Manley, Geoffrey, Marsteller, Jill, Mascia, Luciana, Mcfadyen, Charle, Mondello, Stefania, Newcombe, Virginia, Palotie, Aarno, Parizel, Paul M, Peul, Wilco, Piercy, Jame, Polinder, Suzanne, Puybasset, Loui, Rasmussen, Todd E, Rossaint, Rolf, Smielewski, Peter, Söderberg, Jeannette, Stanworth, Simon J, Stein, Murray B, von Steinbüchel, Nicole, Stewart, William, Steyerberg, Ewout W, Stocchetti, Nino, Synnot, Anneliese, Te Ao, Braden, Tenovuo, Olli, Theadom, Alice, Tibboel, Dick, Videtta, Walter, Wang, Kevin K W, Williams, W Huw, Wilson, Lindsay, Yaffe, Kristine, InTBIR Participants, Investigator, Beretta, Luigi, InTBIR Participants Investigators, Menon, David [0000-0002-3228-9692], Czosnyka, Marek [0000-0003-2446-8006], Ercole, Ari [0000-0001-8350-8093], Newcombe, Virginia [0000-0001-6044-9035], Smielewski, Peter [0000-0001-5096-3938], Apollo - University of Cambridge Repository, Maas A.I.R., Menon D.K., David Adelson P.D., Andelic N., Bell M.J., Belli A., Bragge P., Brazinova A., Buki A., Chesnut R.M., Citerio G., Coburn M., Jamie Cooper D., Tamara Crowder A., Czeiter E., Czosnyka M., Diaz-Arrastia R., Dreier J.P., Duhaime A.-C., Ercole A., van Essen T.A., Feigin V.L., Gao G., Giacino J., Gonzalez-Lara L.E., Gruen R.L., Gupta D., Hartings J.A., Hill S., Jiang J.-Y., Ketharanathan N., Kompanje E.J.O., Lanyon L., Laureys S., Lecky F., Levin H., Lingsma H.F., Maegele M., Majdan M., Manley G., Marsteller J., Mascia L., McFadyen C., Mondello S., Newcombe V., Palotie A., Parizel P.M., Peul W., Piercy J., Polinder S., Puybasset L., Rasmussen T.E., Rossaint R., Smielewski P., Soderberg J., Stanworth S.J., Stein M.B., von Steinbuchel N., Stewart W., Steyerberg E.W., Stocchetti N., Synnot A., Te Ao B., Tenovuo O., Theadom A., Tibboel D., Videtta W., Wang K.K.W., Huw Williams W., Wilson L., Yaffe K., Adams H., Allanson J., Coles J., Hutchinson P.J., Kolias A.G., Sahakian B.J., Stamatakis E., Williams G., Agnoletti V., Martino C., Masala A., Teodorani G., Zumbo F., Amrein K., Ezer E., Kolumban B., Kovacs N., Melegh B., Nyiradi J., Sorinola A., Vamos Z., Andaluz N., Anke A., Frisvold S.K., Antoni A., van As A.B., Figaji A., Audibert G., Azasevac A., Dilvesi D., Golubovic J., Jelaca B., Karan M., Kolundzija K., Negru A., Vulekovic P., Azouvi P., Azzolini M.L., Beretta L., Baciu C., Beqiri V., Chevallard G., Chieregato A., Sacchi M., Badenes R., Belda F.J., Bilotta F., Lozano A., Barlow K.M., Schneider K.J., Bartels R., den Boogert H., Hoedemaekers C., Sir O., Bauerfeind U., Lefering R., Schafer N., Beauchamp M., Gravel J., Beer D., Beer R., Helbok R., Hofer S., Bellander B.-M., Nelson D., Bellier R., Benard T., Carise E., Dahyot-Fizelier C., Giraud B., Benali H., Bernard F., Bertolini G., Masson S., Blaabjerg M., Rosenlund C., Schou R.F., Boutis K., Bouzat P., Francony G., Manhes P., Payen J.-F., Brooks B., Dewey D., Emery C.A., Freedman S., Kramer A., Brorsson C., Koskinen L.-O., Sundstrom N., Bullinger M., Burns E., Calappi E., Ortolano F., Cameron P., Castano-Leon A.M., Gomez Lopez P.A., Lagares A., Causin F., Freo U., Persona P., Rossi S., Christie B., Cnossen M., Dippel D., Foks K., Haagsma J.A., Haitsma I., Huijben J.A., van der Jagt M., Nieboer D., Volovici V., Voormolen D.C., Collett J., Dawes H., Esser P., van Heugten C., Della Corte F., Grossi F., Craig W., Csato G., Csomos A., Curry N., Dematteo C., Meade M., Depreitere B., van Dijck J., de Ruiter G.C.W., Vleggeert-Lankamp C., Dizdarevic K., Donoghue E., Gantner D., Murray L., Trapani T., Vallance S., Duek O., Lazar I., Duliere G.-L., Marechal H., Dzeko A., Eapen G., Jankowski S., English S., Fergusson D., Osmond M., Fabricius M., Kondziella D., Feng J., Hui J., Fleming J., Latini R., Gagnon I., Ptito A., Galanaud D., Glocker B., Kamnitsas K., Ledig C., Rueckert D., Gordon W.A., Gradisek P., Griesdale D., Haberg A.K., van Hecke W., Smeets D., Verheyden J., Vyvere T.V., Helseth E., Roe C., Roise O., Horton L., Jacobs B., van der Naalt J., Janssens K., De Keyser V., Menovsky T., Van Praag D., Jones K.M., Kaps R., Katila A., Posti J., Takala R., Kaukonen K.-M., Kivisaari R., Piippo-Karjalainen A., Raj R., Tanskanen P., Kutsogiannis D., Kyprianou T., Lamontagne F., Lauzier F., Moore L., Turgeon A., Legrand V., Levi L., Zaaroor M., Lightfoot R., Macdonald S., Major S., Vajkoczy P., Wessels L., Winkler M.K.L., Wolf S., Manara A., Thomas M., Mattern J., Sakowitz O., Vogt L., Younsi A., McFadyen B., McMahon C., Correia M.M., Morganti-Kossmann M.C., Rosenfeld J.V., Muehlan H., Schmidt S., Mukherjee P., Noirhomme Q., Oddo M., Okonkwo D.O., Oldenbeuving A.W., Roks G., Schoonman G.G., Perlbarg V., Pichon N., Pili-Floury S., Pirinen M., Ples H., Poca M.A., Radoi A., Sahuquillo J., Ragauskas A., Rocka S., Real R.G.L., Telgmann R., Reed N., Rhodes J., Robertson C., Rosand J., Rosenthal G., Salvato G., Sanchez-Porras R., Sandor J., Sangha G., Schnyer D., Schohl H., Skandsen T., Stevanovic A., van Waesberghe J.V., Stevens R.D., Taccone F.S., Taylor M.S., Zelinkova V., Temkin N., Tolias C.M., Valadka A.B., Valeinis E., Vargiolu A., Vega E., Vik A., Vilcinis R., Wildschut E., Wood G., Xirouchaki N., Zemek R., Maas, A, Menon, D, Adelson, P, Andelic, N, Bell, M, Belli, A, Bragge, P, Brazinova, A, Büki, A, Chesnut, R, Citerio, G, Coburn, M, Cooper, D, Crowder, A, Czeiter, E, Czosnyka, M, Diaz arrastia, R, Dreier, J, Duhaime, A, Ercole, A, Van Essen, T, Feigin, V, Gao, G, Giacino, J, Gonzalez lara, L, Gruen, R, Gupta, D, Hartings, J, Hill, S, Jiang, J, Ketharanathan, N, Kompanje, E, Lanyon, L, Laureys, S, Lecky, F, Levin, H, Lingsma, H, Maegele, M, Majdan, M, Manley, G, Marsteller, J, Mascia, L, Mcfadyen, C, Mondello, S, Newcombe, V, Palotie, A, Parizel, P, Peul, W, Piercy, J, Polinder, S, Puybasset, L, Rasmussen, T, Rossaint, R, Smielewski, P, Söderberg, J, Stanworth, S, Stein, M, Von Steinbüchel, N, Stewart, W, Steyerberg, E, Stocchetti, N, Synnot, A, Te Ao, B, Tenovuo, O, Theadom, A, Tibboel, D, Videtta, W, Wang, K, Williams, W, Wilson, L, Yaffe, K, Adams, H, Agnoletti, V, Allanson, J, Amrein, K, Andaluz, N, Anke, A, Antoni, A, Van As, A, Audibert, G, Azaševac, A, Azouvi, P, Azzolini, M, Baciu, C, Badenes, R, Barlow, K, Bartels, R, Bauerfeind, U, Beauchamp, M, Beer, D, Beer, R, Belda, F, Bellander, B, Bellier, R, Benali, H, Benard, T, Beqiri, V, Beretta, L, Bernard, F, Bertolini, G, Bilotta, F, Blaabjerg, M, Den Boogert, H, Boutis, K, Bouzat, P, Brooks, B, Brorsson, C, Bullinger, M, Burns, E, Calappi, E, Cameron, P, Carise, E, Castaño león, A, Causin, F, Chevallard, G, Chieregato, A, Christie, B, Cnossen, M, Coles, J, Collett, J, Della Corte, F, Craig, W, Csato, G, Csomos, A, Curry, N, Dahyot fizelier, C, Dawes, H, Dematteo, C, Depreitere, B, Dewey, D, Van Dijck, J, Đilvesi, Đ, Dippel, D, Dizdarevic, K, Donoghue, E, Duek, O, Dulière, G, Dzeko, A, Eapen, G, Emery, C, English, S, Esser, P, Ezer, E, Fabricius, M, Feng, J, Fergusson, D, Figaji, A, Fleming, J, Foks, K, Francony, G, Freedman, S, Freo, U, Frisvold, S, Gagnon, I, Galanaud, D, Gantner, D, Giraud, B, Glocker, B, Golubovic, J, Gómez López, P, Gordon, W, Gradisek, P, Gravel, J, Griesdale, D, Grossi, F, Haagsma, J, Håberg, A, Haitsma, I, Van Hecke, W, Helbok, R, Helseth, E, Van Heugten, C, Hoedemaekers, C, Höfer, S, Horton, L, Hui, J, Huijben, J, Hutchinson, P, Jacobs, B, Van Der Jagt, M, Jankowski, S, Janssens, K, Jelaca, B, Jones, K, Kamnitsas, K, Kaps, R, Karan, M, Katila, A, Kaukonen, K, De Keyser, V, Kivisaari, R, Kolias, A, Kolumbán, B, Kolundžija, K, Kondziella, D, Koskinen, L, Kovács, N, Kramer, A, Kutsogiannis, D, Kyprianou, T, Lagares, A, Lamontagne, F, Latini, R, Lauzier, F, Lazar, I, Ledig, C, Lefering, R, Legrand, V, Levi, L, Lightfoot, R, Lozano, A, Macdonald, S, Major, S, Manara, A, Manhes, P, Maréchal, H, Martino, C, Masala, A, Masson, S, Mattern, J, Mcfadyen, B, Mcmahon, C, Meade, M, Melegh, B, Menovsky, T, Moore, L, Morgado Correia, M, Morganti kossmann, M, Muehlan, H, Mukherjee, P, Murray, L, Van Der Naalt, J, Negru, A, Nelson, D, Nieboer, D, Noirhomme, Q, Nyirádi, J, Oddo, M, Okonkwo, D, Oldenbeuving, A, Ortolano, F, Osmond, M, Payen, J, Perlbarg, V, Persona, P, Pichon, N, Piippo karjalainen, A, Pili floury, S, Pirinen, M, Ple, H, Poca, M, Posti, J, Van Praag, D, Ptito, A, Radoi, A, Ragauskas, A, Raj, R, Real, R, Reed, N, Rhodes, J, Robertson, C, Rocka, S, Røe, C, Røise, O, Roks, G, Rosand, J, Rosenfeld, J, Rosenlund, C, Rosenthal, G, Rossi, S, Rueckert, D, De Ruiter, G, Sacchi, M, Sahakian, B, Sahuquillo, J, Sakowitz, O, Salvato, G, Sánchez porras, R, Sándor, J, Sangha, G, Schäfer, N, Schmidt, S, Schneider, K, Schnyer, D, Schöhl, H, Schoonman, G, Schou, R, Sir, Ö, Skandsen, T, Smeets, D, Sorinola, A, Stamatakis, E, Stevanovic, A, Stevens, R, Sundström, N, Taccone, F, Takala, R, Tanskanen, P, Taylor, M, Telgmann, R, Temkin, N, Teodorani, G, Thomas, M, Tolias, C, Trapani, T, Turgeon, A, Vajkoczy, P, Valadka, A, Valeinis, E, Vallance, S, Vámos, Z, Vargiolu, A, Vega, E, Verheyden, J, Vik, A, Vilcinis, R, Vleggeert lankamp, C, Vogt, L, Volovici, V, Voormolen, D, Vulekovic, P, Vande Vyvere, T, Van Waesberghe, J, Wessels, L, Wildschut, E, Williams, G, Winkler, M, Wolf, S, Wood, G, Xirouchaki, N, Younsi, A, Zaaroor, M, Zelinkova, V, Zemek, R, Zumbo, F, Pediatric Surgery, Intensive Care, and Public Health

Subjects
medicine.medical_specialty, EVIDENCE-BASED MEDICINE, Treatment outcome, Poison control, Other Research Radboud Institute for Molecular Life Sciences [Radboudumc 0], EMERGENCY-DEPARTMENT VISITS, Review, PLACEBO-CONTROLLED TRIAL, Middle income country, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18], 03 medical and health sciences, 0302 clinical medicine, Intensive care, Brain Injuries, Traumatic, Journal Article, medicine, traumatic barin injury, Humans, 030212 general & internal medicine, Clinical care, Neurologic disease, Psychiatry, DIAGNOSTIC MANAGEMENT STRATEGIES, business.industry, RANDOMIZED CONTROLLED-TRIAL, ACUTE SUBDURAL-HEMATOMA, SEVERE HEAD-INJURY, ROAD TRAFFIC INJURIES, brain injury, Hospital care, 3. Good health, Reconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10], Brain Injuries, Health care cost, PATIENT-REPORTED OUTCOMES, Human medicine, Neurology (clinical), business, Humanities, 030217 neurology & neurosurgery, GLASGOW COMA SCALE
Abstract

Executive summary A concerted effort to tackle the global health problem posed by traumatic brain injury (TBI) is long overdue. TBI is a public health challenge of vast, but insufficiently recognised, proportions. Worldwide, more than 50 million people have a TBI each year, and it is estimated that about half the world’s population will have one or more TBIs over their lifetime. TBI is the leading cause of mortality in young adults and a major cause of death and disability across all ages in all countries, with a disproportionate burden of disability and death occurring in low-income and middle-income countries (LMICs). It has been estimated that TBI costs the global economy approximately $US400 billion annually. Deficiencies in prevention, care, and research urgently need to be addressed to reduce the huge burden and societal costs of TBI. This Commission highlights priorities and provides expert recommendations for all stakeholders— policy makers, funders, health-care professionals, researchers, and patient representatives—on clinical and research strategies to reduce this growing public health problem and improve the lives of people with TBI. The epidemiology of TBI is changing: in high-income countries, the number of elderly people with TBI is increasing, mainly due to falls, while in LMICs, the burden of TBI from road traffic incidents is increasing. Data on the frequency of TBI and TBI-related deaths and on the economic impact of brain trauma are often incomplete and vary between countries. Improved, accurate epidemiological monitoring and robust healtheconomic data collection are needed to inform healthcare policy and prevention programmes. Highly developed and coordinated systems of care are crucial for management of patients with TBI. However, in practice, implementation of such frameworks varies greatly and disconnects exist in the chain of care. Optimisation of systems of care should be high on the policy agenda and could yield substantial gains in terms of both patient outcomes and costs to society. TBI is a complex condition, and strong evidence to support treatment guidelines and recommendations is scarce. Most multicentre clinical trials of medical and surgical interventions have failed to show efficacy, despite promising preclinical results. At the bedside, treatment strategies are generally based on guidelines that promote a one-size-fits-all approach and are insufficiently targeted to the needs of individual patients. Attempts to individualise treatment are challenging owing to the diversity of TBI, and are hampered by the use of simplistic methods to characterise its initial type and severity. Advances in genomics, blood biomarkers, magnetic resonance imaging (MRI), and pathophysiological monitoring, combined with informatics to integrate data from multiple sources, offer new research avenues to improve disease characterisation and monitoring of disease evolution. These tools can also aid understanding of disease mechanisms and facilitate targeted treatment strategies for individual patients. Individualised management in the postacute phase and evaluation of the effectiveness of treatment and care processes depend on accurate quantification of outcomes. In practice, however, the use of simplistic methods hinders efforts to quantify outcomes after TBI of all severities. Development and validation of multidimensional approaches will be essential to improve measurement of clinical outcomes, for both research and patient care. In particular, we need to find better ways to characterise the currently under-recognised risk of long-term disabling sequelae in patients with relatively mild injuries. Prognostic models are important to help clinicians to provide reliable information to patients and relatives, and to facilitate comparative audit of care between centres and countries. There is an urgent need for further development, validation, and implementation of prognostic models in TBI, particularly for less severe TBI. This multitude of challenges in TBI—encompassing systems of care, clinical management, and research strategy—demands novel approaches to the generation of new evidence and its implementation in clinical practice. Comparative effectiveness research (CER) offers opportunities to capitalise on the diversity of TBI and systems of care and enables assessment of therapies in real-world conditions; high-quality CER studies can provide strong evidence to support guideline recommendations. The global challenges posed by TBI necessitate global collaborations and a change in research culture to endorse broad data sharing. This Commission covers a range of topics that need to be addressed to confront the global burden of TBI and reduce its effects on individuals and society: epidemiology (section 1); health economics (section 2); prevention (section 3); systems of care (section 4); clinical management (section 5); characterisation of TBI (section 6); outcome assessment (section 7); prognosis (section 8); and new directions for acquiring and implementing evidence (section 9). Table 1 summarises key messages from the Commission and provides recommendations to advance clinical care and research in TBI. We must increase awareness of the scale of the challenge posed by TBI. If we are to tackle the individual and societal burden of TBI, these efforts need to go beyond a clinical and research audience and address the public, politicians, and other stakeholders. We need to develop and implement policies for better prevention and systems of care in order to improve outcomes for individuals with TBI. We also need a commitment to substantial long-term investment in TBI research across a range of disciplines to determine best practice and facilitate individualised management strategies. A combination of innovative research methods and global collaboration, and ways to effectively translate progress in basic and clinical research into clinical practice and public health policy, will be vital for progress in the field.

Published
2017
Full Text
View/download PDF

8. Brain death and postmortem organ donation: report of a questionnaire from the CENTER-TBI study

Author

Van Veen E., Van Der Jagt M., Cnossen M. C., Maas A. I. R., De Beaufort I. D., Menon D. K., Citerio G., Stocchetti N., Rietdijk W. J. R., Van Dijck J. T. J. M., Kompanje E. J. O., Ackerlund C., Adams H., Agnoletti V., Allanson J., Amrein K., Andaluz N., Andelic N., Andreassen L., Antun A., Anke A., Antoni A., Ardon H., Audibert G., Auslands K., Azouvi P., Azzolini M. L., Baciu C., Badenes R., Bartels R., Barzo P., Bauerfeind U., Beauvais R., Beer R., Francisco J. B., Bellander B. -M., Belli A., Bellier R., Benali H., Benard T., Berardino M., Beretta L., Beynon C., Bilotta F., Binder H., Biqiri E., Blaabjerg M., Den Boogert H., Bouzat P., Bragge P., Brazinova A., Brinck V., Brooker J., Brorsson C., Buki A., Bullinger M., Calappi E., Calvi M. R., Cameron P., Lozano G. C., Carbonara M., Carise E., Carpenter K., Castano-Leon A. M., Causin F., Chevallard G., Chieregato A., Coburn M., Coles J., Coles-Kemp L., Collett J., Cooper J. D., Correia M., Covic A., Curry N., Czeiter E., Czosnyka M., Dahyot-Fizelier C., Damas F., Damas P., Dawes H., De Keyser V., Della Corte F., Depreitere B., De Ruiter Godard C. W., Dilvesi D., Ding S., Dippel D., Dixit A., Donoghue E., Dreier J., Duliere G. -L., Eapen G., Engemann H., Ercole A., Esser P., Ezer E., Fabricius M., Feigin V. L., Feng J., Foks K., Fossi F., Francony G., Freo U., Frisvold S., Furmanov A., Gagliardo P., Galanaud D., Gantner D., Gao G., Geleijns K., George P., Ghuysen A., Giga L., Giraud B., Glocker B., Golubovic J., Gomez P. A., Grossi F., Gruen R. L., Gupta D., Haagsma J. A., Haitsma I., Hartings J. A., Helbok R., Helseth E., Hertle D., Hoedemaekers A., Hoefer S., Horton L., Huijben J., Hutchinson P. J., Haberg A. K., Jacobs B., Jankowski S., Jarrett M., Jelaca B., Jiang J. -Y., Jones K., Kamnitsas K., Karan M., Katila A., Kaukonen M., Kerforne T., Kivisaari R., Kolias A. G., Kolumban B., Kolundzija K., Kondziella D., Koskinen L. -O., Kovacs N., Lagares A., Lanyon L., Laureys S., Lecky F., Ledig C., Lefering R., Legrand V., Lei J., Levi L., Lightfoot R., Lingsma H., Loeckx D., Lozano A., MacDonald S., Maegele M., Majdan M., Major S., Manara A., Manley G., Didier M., Martin L. F., Martino C., Maruenda A., Marechal H., Masala A., Mattern J., McFadyen C., McMahon C., Melegh B., Menovsky T., Morganti-Kossmann C., Mulazzi D., Muraleedharan V., Murray L., Muhlan H., Nair N., Negru A., Nelson D., Newcombe V., Nieboer D., Noirhomme Q., Nyiradi J., Oddo M., Oldenbeuving A., Oresic M., Ortolano F., Palotie A., Parizel P. M., Patruno A., Payen J. -F., Perera N., Perlbarg V., Persona P., Peul W., Piippo-Karjalainen A., Floury S. P., Pirinen M., Ples H., Poca M. A., Polinder S., Pomposo I., Posti J., Puybasset L., Radoi A., Ragauskas A., Raj R., Rambadagalla M., Real R., Rehorcikova V., Rhodes J., Ripatti S., Rocka S., Roe C., Roise O., Roks G., Rosand J., Rosenfeld J., Rosenlund C., Rosenthal G., Rossaint R., Rossi S., Rueckert D., Rusnak M., Sacchi M., Sahakian B., Sahuquillo J., Sakowitz O., Sala F., Sanchez-Porras R., Sandor J., Santos E., Sasu L., Savo D., Schaffer N., Schipper I., Schlosser B., Schmidt S., Schoechl H., Schoonman G., Schou R. F., Schwendenwein E., Scholl M., Sir O., Skandsen T., Smakman L., Smeets D., Smielewski P., Sorinola A., Stamatakis E., Stanworth S., Steinbuchel N., Stevanovic A., Stevens R., Stewart W., Steyerberg E. W., Sundstrom N., Synnot A., Taccone F. S., Takala R., Tamas V., Tanskanen P., Taylor M. S., Te Ao B., Tenovuo O., Telgmann R., Teodorani G., Theadom A., Thomas M., Tibboel D., Tolias C., Tshibanda J. -F. L., Trapani T., Tudora C. M., Vajkoczy P., Vallance S., Valeinis E., Van Der Steen G., Van Der Naalt J., Van Essen T. A., Van Hecke W., Van Heugten C., Van Praag D., Vyvere T. V., Van Waesberghe J., Vanhaudenhuyse A., Vargiolu A., Vega E., Velt K., Verheyden J., Vespa P. M., Vik A., Vilcinis R., Vizzino G., Vleggeert-Lankamp C., Volovici V., Voormolen D., Vulekovic P., Vamos Z., Wade D., Wang K. K. W., Wang L., Wessels L., Wildschut E., Williams G., Wilson L., Winkler M. K. L., Wolf S., Ylen P., Younsi A., Zaaroor M., Zhihui Y., Ziverte A., Zumbo F., Intensive Care, Public Health, van Veen, Ernest, van der Jagt, Mathieu, Cnossen, Maryse C., Maas, Andrew I R, de Beaufort, Inez D., Menon, David K., Citerio, Giuseppe, Stocchetti, Nino, Rietdijk, Wim J R, van Dijck, Jeroen T J M, Kompanje, Erwin J O (CENTER-TBI investigators and participants), Beretta, Luigi, Apollo - University of Cambridge Repository, Ragauskas, Arminas, Rocka, Saulius, Vilcinis, Rimantas, „Springer' grupė, Neurokirurgian yksikkö, Clinicum, Van Veen E., Van Der Jagt M., Cnossen M.C., Maas A.I.R., De Beaufort I.D., Menon D.K., Citerio G., Stocchetti N., Rietdijk W.J.R., Van Dijck J.T.J.M., Kompanje E.J.O., Ackerlund C., Adams H., Agnoletti V., Allanson J., Amrein K., Andaluz N., Andelic N., Andreassen L., Antun A., Anke A., Antoni A., Ardon H., Audibert G., Auslands K., Azouvi P., Azzolini M.L., Baciu C., Badenes R., Bartels R., Barzo P., Bauerfeind U., Beauvais R., Beer R., Francisco J.B., Bellander B.-M., Belli A., Bellier R., Benali H., Benard T., Berardino M., Beretta L., Beynon C., Bilotta F., Binder H., Biqiri E., Blaabjerg M., Den Boogert H., Bouzat P., Bragge P., Brazinova A., Brinck V., Brooker J., Brorsson C., Buki A., Bullinger M., Calappi E., Calvi M.R., Cameron P., Lozano G.C., Carbonara M., Carise E., Carpenter K., Castano-Leon A.M., Causin F., Chevallard G., Chieregato A., Coburn M., Coles J., Coles-Kemp L., Collett J., Cooper J.D., Correia M., Covic A., Curry N., Czeiter E., Czosnyka M., Dahyot-Fizelier C., Damas F., Damas P., Dawes H., De Keyser V., Della Corte F., Depreitere B., De Ruiter Godard C.W., Dilvesi D., Ding S., Dippel D., Dixit A., Donoghue E., Dreier J., Duliere G.-L., Eapen G., Engemann H., Ercole A., Esser P., Ezer E., Fabricius M., Feigin V.L., Feng J., Foks K., Fossi F., Francony G., Freo U., Frisvold S., Furmanov A., Gagliardo P., Galanaud D., Gantner D., Gao G., Geleijns K., George P., Ghuysen A., Giga L., Giraud B., Glocker B., Golubovic J., Gomez P.A., Grossi F., Gruen R.L., Gupta D., Haagsma J.A., Haitsma I., Hartings J.A., Helbok R., Helseth E., Hertle D., Hoedemaekers A., Hoefer S., Horton L., Huijben J., Hutchinson P.J., Haberg A.K., Jacobs B., Jankowski S., Jarrett M., Jelaca B., Jiang J.-Y., Jones K., Kamnitsas K., Karan M., Katila A., Kaukonen M., Kerforne T., Kivisaari R., Kolias A.G., Kolumban B., Kolundzija K., Kondziella D., Koskinen L.-O., Kovacs N., Lagares A., Lanyon L., Laureys S., Lecky F., Ledig C., Lefering R., Legrand V., Lei J., Levi L., Lightfoot R., Lingsma H., Loeckx D., Lozano A., MacDonald S., Maegele M., Majdan M., Major S., Manara A., Manley G., Didier M., Martin L.F., Martino C., Maruenda A., Marechal H., Masala A., Mattern J., McFadyen C., McMahon C., Melegh B., Menovsky T., Morganti-Kossmann C., Mulazzi D., Muraleedharan V., Murray L., Muhlan H., Nair N., Negru A., Nelson D., Newcombe V., Nieboer D., Noirhomme Q., Nyiradi J., Oddo M., Oldenbeuving A., Oresic M., Ortolano F., Palotie A., Parizel P.M., Patruno A., Payen J.-F., Perera N., Perlbarg V., Persona P., Peul W., Piippo-Karjalainen A., Floury S.P., Pirinen M., Ples H., Poca M.A., Polinder S., Pomposo I., Posti J., Puybasset L., Radoi A., Ragauskas A., Raj R., Rambadagalla M., Real R., Rehorcikova V., Rhodes J., Ripatti S., Rocka S., Roe C., Roise O., Roks G., Rosand J., Rosenfeld J., Rosenlund C., Rosenthal G., Rossaint R., Rossi S., Rueckert D., Rusnak M., Sacchi M., Sahakian B., Sahuquillo J., Sakowitz O., Sala F., Sanchez-Porras R., Sandor J., Santos E., Sasu L., Savo D., Schaffer N., Schipper I., Schlosser B., Schmidt S., Schoechl H., Schoonman G., Schou R.F., Schwendenwein E., Scholl M., Sir O., Skandsen T., Smakman L., Smeets D., Smielewski P., Sorinola A., Stamatakis E., Stanworth S., Steinbuchel N., Stevanovic A., Stevens R., Stewart W., Steyerberg E.W., Sundstrom N., Synnot A., Taccone F.S., Takala R., Tamas V., Tanskanen P., Taylor M.S., Te Ao B., Tenovuo O., Telgmann R., Teodorani G., Theadom A., Thomas M., Tibboel D., Tolias C., Tshibanda J.-F.L., Trapani T., Tudora C.M., Vajkoczy P., Vallance S., Valeinis E., Van Der Steen G., Van Der Naalt J., Van Essen T.A., Van Hecke W., Van Heugten C., Van Praag D., Vyvere T.V., Van Waesberghe J., Vanhaudenhuyse A., Vargiolu A., Vega E., Velt K., Verheyden J., Vespa P.M., Vik A., Vilcinis R., Vizzino G., Vleggeert-Lankamp C., Volovici V., Voormolen D., Vulekovic P., Vamos Z., Wade D., Wang K.K.W., Wang L., Wessels L., Wildschut E., Williams G., Wilson L., Winkler M.K.L., Wolf S., Ylen P., Younsi A., Zaaroor M., Zhihui Y., Ziverte A., Zumbo F., Section Neuropsychology, RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, RS: FPN NPPP I, Psychiatrie & Neuropsychologie, Menon, David [0000-0002-3228-9692], Ročka, Saulius, Molecular Neuroscience and Ageing Research (MOLAR), CENTER-TBI Investigators, van Veen, E, van der Jagt, M, Cnossen, M, Maas, A, de Beaufort, I, Menon, D, Citerio, G, Stocchetti, N, Rietdijk, W, van Dijck, J, and Kompanje, E

Subjects
Neurology, Internationality, Traumatic/complications, brain death, ethics, postmortem organ donation, traumatic brain injury, ventricular drainage, withdrawing life-sustaining measures, GUIDELINES, Critical Care and Intensive Care Medicine, 0302 clinical medicine, Traumatic brain injury, Trauma Centers, WORLDWIDE, Surveys and Questionnaires, Brain Injuries, Traumatic, Response rate (survey), Brain death, VDP::Medical disciplines: 700::Clinical medical disciplines: 750, VDP::Medisinske Fag: 700::Klinisk medisinske fag: 750, lcsh:Medical emergencies. Critical care. Intensive care. First aid, Tissue and Organ Procurement/legislation & jurisprudence, POLICIES, Europe, VARIABILITY, Neurosurgery, Clinical evaluation, medicine.medical_specialty, Tissue and Organ Procurement, Withdrawing life-sustaining measure, Other Research Radboud Institute for Molecular Life Sciences [Radboudumc 0], Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18], 03 medical and health sciences, Neurological assessment, medicine, Humans, Organ donation, Ethics, Postmortem organ donation, Ventricular drainage, Withdrawing life-sustaining measures, Ethic, business.industry, Research, Brain Injuries, Traumatic/complications, 3112 Neurosciences, 030208 emergency & critical care medicine, ADULTS, lcsh:RC86-88.9, Traumatic brain injury, Brain death, Ethics, Postmortem organ donation, Withdrawing life-sustaining measures, Ventricular drainage, medicine.disease, 3126 Surgery, anesthesiology, intensive care, radiology, Reconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10], Trauma Centers/organization & administration, Brain Injuries, Emergency medicine, Human medicine, business, 030217 neurology & neurosurgery, Regional differences
Abstract

Source at https://doi.org/10.1186/s13054-018-2241-4. Licensed CC BY-NC-ND 4.0. Background: We aimed to investigate the extent of the agreement on practices around brain death and postmortem organ donation. Methods: Investigators from 67 Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) study centers completed several questionnaires (response rate: 99%). Results: Regarding practices around brain death, we found agreement on the clinical evaluation (prerequisites and neurological assessment) for brain death determination (BDD) in 100% of the centers. However, ancillary tests were required for BDD in 64% of the centers. BDD for nondonor patients was deemed mandatory in 18% of the centers before withdrawing life-sustaining measures (LSM). Also, practices around postmortem organ donation varied. Organ donation after circulatory arrest was forbidden in 45% of the centers. When withdrawal of LSM was contemplated, in 67% of centers the patients with a ventricular drain in situ had this removed, either sometimes or all of the time. Conclusions: This study showed both agreement and some regional differences regarding practices around brain death and postmortem organ donation. We hope our results help quantify and understand potential differences, and provide impetus for current dialogs toward further harmonization of practices around brain death and postmortem organ donation.

Published
2018
Full Text
View/download PDF

9. Variation in neurosurgical management of traumatic brain injury: a survey in 68 centers participating in the CENTER-TBI study (vol 161, pg 453, 2019)

Author

den Boogert H, Cnossen M, Lingsma H, Peul W, Ackerlund C, Adams H, Agnoletti V, Allanson J, Amrein K, Andaluz N, Andelic N, Andreassen L, Antun A, Anke A, Antoni A, Ardon H, Audibert G, Auslands K, Azouvi P, Azzolini M, Baciu C, Badenes R, Bartels R, Barzo P, Bauerfeind U, Beauvais R, Beer R, Belda F, Bellander B, Belli A, Bellier R, Benali H, Benard T, Berardino M, Beretta L, Beynon C, Bilotta F, Binder H, Biqiri E, Blaabjerg M, Bouzat P, Bragge P, Brazinova A, Brinck V, Brooker J, Brorsson C, Buki A, Bullinger M, Calappi E, Calvi M, Cameron P, Carbayo L, Carbonara M, Carise E, Carpenter K, Castano-Leon A, Causin F, Chevallard G, Chieregato A, Citerio G, Coburn M, Coles J, Coles-Kemp L, Collett J, Cooper J, Correia M, Covic A, Curry N, Czeiter E, Czosnyka M, Dahyot-Fizelier C, Damas F, Damas P, Dawes H, De Keyser V, Francesco D, Depreitere B, de Ruiter G, Dilvesi D, Ding S, Dippel D, Dixit A, Donoghue E, Dreier J, Duliere G, Eapen G, Engemann H, Ercole A, Esser P, Ezer E, Fabricius M, Feigin V, Feng J, Foks K, Fossi F, Francony G, Freo U, Frisvold S, Furmanov A, Gagliardo P, Galanaud D, Gantner D, Gao G, Geleijns K, George P, Ghuysen A, Giga L, Giraud B, Ben Glocker, Golubovic J, Gomez P, Grossi F, Gruen R, Gupta D, Haagsma J, Haitsma I, Hartings J, Helbok R, Helseth E, Hertle D, Hoedemaekers A, Hoefer S, Horton L, Huijben J, Hutchinson P, Haberg A, Jacobs B, Jankowski S, Jarrett M, Jelaca B, Jiang J, Jones K, Kamnitsas K, Karan M, Katila A, Kaukonen M, Kerforne T, Kivisaari R, Kolias A, Kolumban B, Kompanje E, Kolundzija K, Kondziella D, Koskinen L, Kovacs N, Lagares A, Lanyon L, Laureys S, Lecky F, Ledig C, Lefering R, Legrand V, Lei J, Levi L, Lightfoot R, Loeckx D, Lozano A, Maas A, MacDonald S, Maegele M, Majdan M, Major S, Manara A, Manley G, Martin D, Martin L, Martino C, Maruenda A, Marechal H, Masala A, Mattern J, McFadyen C, McMahon C, Melegh B, Menon D, Menovsky T, Morganti-Kossmann C, Mulazzi D, Muraleedharan V, Murray L, Muhlan H, Nair N, Negru A, Nelson D, Newcombe V, Nieboer D, Noirhomme Q, Nyiradi J, Oddo M, Oldenbeuving A, Oresic M, Ortolano F, Palotie A, Parizel P, Patruno A, Payen J, Perera N, Perlbarg V, Persona P, Piippo-Karjalainen A, Pili F, Pirinen M, Ples H, Poca M, Polinder S, Pomposo I, Posti J, Puybasset L, Radoi A, Ragauskas A, Raj R, Rambadagalla M, Real R, Rehorcikova V, Rhodes J, Ripatti S, Rocka S, Roe C, Roise O, Roks G, Rosand J, Rosenfeld J, Rosenlund C, Rosenthal G, Rossaint R, Rossi S, Rueckert D, Rusnak M, Sacchi M, Sahakian B, Sahuquillo J, Sakowitz O, Sala F, Sanchez-Porras R, Sandor J, Santos E, Sasu L, Savo D, Schaffer N, Schipper I, Schlosser B, Schmidt S, Schoechl H, Schoonman G, Schou R, Schwendenwein E, Scholl M, Sir O, Skandsen T, Smakman L, Smeets D, Smielewski P, Sorinola A, Stamatakis E, Stanworth S, Steinbuchel N, Stevanovic A, Stevens R, Stewart W, Steyerberg E, Stocchetti N, Sundstrom N, Synnot A, Taccone F, Takala R, Tamas V, Tanskanen P, Taylor M, Ao B, Tenovuo O, Telgmann R, Teodorani G, Theadom A, Thomas M, Tibboel D, Tolias C, Tshibanda J, Trapani T, Tudora C, Vajkoczy P, Vallance S, Valeinis E, Van der Steen G, van der Jagt M, van der Naalt J, van Dijck J, van Essen T, van Hecke W, van Heugten C, van Praag D, Vyvere T, Van Waesberghe J, Vanhaudenhuyse A, Vargiolu A, Vega E, Velt K, Verheyden J, Vespa P, Vik A, Vilcinis R, Vizzino G, Vleggeert-Lankamp C, Volovici V, Voormolen D, Vulekovic P, Vamos Z, Wade D, Wang K, Wang L, Wessels L, Wildschut E, Williams G, Wilson L, Winkler M, Wolf S, Ylen P, Younsi A, Zaaroor M, Yang Z, Ziverte A, Zumbo F, and CENTER-TBI Investigators

Published
2019

14. Richtlijn diagnostiek en behandeling van dementie

Author

Olde Rikkert, M.G., van Exel, E., Knol, W., Lemstra, Afina W., Roks, G., Verhey, Frans, Psychiatrie & Neuropsychologie, MUMC+: MA Med Staf Spec Psychiatrie (9), and RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience

Published
2015

15. Building the fastest bicycle in the world; a year with the Human Power Team Delft & Amsterdam

Author

Schuurman, M. and Roks, G.

Abstract

“Third time lucky” is the saying, but for the third Human Power Team it almost turned out as a year for nothing. The team has been attempting to set the world record for the fastest bicycle powered only by human muscles for two years already. This endeavor to let a Dutchman be the fastest human on earth resulted in a marvelous year with many ups and downs and a world record.

Published
2014

18. Outpatient follow-up after mild traumatic brain injury: Results of the UPFRONT-study.

Author

de Koning, M. E., Scheenen, M. E., van der Horn, H. J., Hageman, G., Roks, G., Yilmaz, T., Spikman, J. M., and van der Naalt, J.

Subjects
BRAIN injuries, CHI-squared test, COMPARATIVE studies, COMPUTED tomography, EMERGENCY medical services, HOSPITAL admission & discharge, PATIENT aftercare, OUTPATIENT services in hospitals, LONGITUDINAL method, EVALUATION of medical care, MEDICAL care use, MEDICAL cooperation, MEDICAL protocols, MEDICAL referrals, NEUROLOGISTS, PATIENTS, PROBABILITY theory, PSYCHIATRISTS, PSYCHOLOGISTS, QUESTIONNAIRES, RESEARCH, SEVERITY of illness index, REHABILITATION for brain injury patients, GLASGOW Coma Scale
Abstract

Objective: To investigate outpatient follow-up after mild traumatic brain injury (mTBI) by various medical specialists, for both hospitalized and non-hospitalized patients, and to study guideline adherence regarding hospital admission.Methods: Patients (n= 1151) with mTBI recruited from the emergency department received questionnaires 2 weeks (n= 879), 3 months (n= 780) and 6 months (n= 668) after injury comprising outpatient follow-up by various health care providers, and outcome defined by the Glasgow Outcome Scale Extended (GOS-E) after 6 months.Results: Hospitalized patients (60%) were older (46.6 ± 19.9 vs. 40.6 ± 18.5 years), more severely injured (GCS <15, 50% vs. 13%) with more Computed Tomography (CT) abnormalities on admission (21% vs. 2%) compared to non-hospitalized patients (p< 0.01) . Almost half of the patients visited a neurologist at the outpatient clinic within six months (60% of the hospitalized and 25% of the non-hospitalized patients (χ2= 67.10,p< 0.01)), and approximately ten per cent consulted a psychiatrist/psychologist. Outcome was unfavourable (GOS-E <7) in 34% of hospitalized and 21% of non-hospitalized patients (χ2= 11.89,p< 0.01).Conclusion: Two-thirds of all mTBI patients consult one or more specialists within six months after injury, with 30% having an unfavourable outcome. A quarter of non-hospitalized patients was seen at the outpatient neurology clinic, underling the importance of regular follow-up of mTBI patients irrespective of hospital admittance. [ABSTRACT FROM PUBLISHER]

Published
2017
Full Text
View/download PDF

19. Additional coiling of previously coiled cerebral aneurysms: Clinical and angiographic results

Author

Slob, M. J., Menno Sluzewski, Rooij, W. J., Roks, G., Rinkel, G. J. E., and University of Groningen

Subjects
GIANT, ENDOVASCULAR TREATMENT, GUGLIELMI DETACHABLE COILS, cardiovascular system, EXPERIENCE, BERRY ANEURYSMS, cardiovascular diseases, RUPTURED INTRACRANIAL ANEURYSMS, EMBOLIZATION
Abstract

BACKGROUND AND PURPOSE: Some cerebral aneurysms that have been coiled reopen over time and additional treatment should be considered to reduce the risk of recurrent hemorrhage. Our purpose was to assess procedural complications and angiographic results of additional coiling in patients with previously coiled but reopened aneurysms and to evaluate protection against (re)bleeding. METHODS: We compared procedural complications of initial coiling of 488 aneurysms in 439 patients with those of 53 additional coiling procedures in 41 reopened aneurysms in 40 patients. Angiographic results of additional coiling were assessed. We compared episodes of (re)bleeding in patients with complete or near-complete aneurysm occlusion after additional coiling with those of patients with incomplete aneurysm occlusion at 6-month follow-up angiography who were not additionally treated or who still had incomplete occlusion after additional coiling. RESULTS: Thirty-five procedural complications occurred in 488 initial coiling procedures, and no complications occurred in 53 additional procedures. Complete or near-complete angiographic occlusion after additional coiling was obtained in 31 (76%) of 41 aneurysms. Rebleeding occurred in two of 29 patients with incomplete aneurysm occlusion but in none of the 31 patients with complete or near-complete occlusion after additional coiling. CONCLUSION. Additional coiling of previously coiled aneurysms has a low procedural complication rate and leads to sufficient occlusion in most aneurysms. The data indicate that successful additional coiling decreases the risk of rebleeding.

Published
2004

25. A pilot study of rivastigmine in the treatment of delirium after stroke: A safe alternative.

Author

Oldenbeuving AW, de Kort PL, Jansen BP, Kappelle LJ, and Roks G

Abstract

Background: Delirium is a common disorder in the early phase of stroke. Given the presumed cholinergic deficiency in delirium, we tested treatment with the acetylcholinesterase inhibitor rivastigmine. Methods: This pilot study was performed within an epidemiological study. In 527 consecutive stroke patients presence of delirium was assessed during the first week with the confusion assessment method. Severity was scored with the delirium rating scale (DRS). Sixty-two patients developed a delirium in the acute phase of stroke. Only patients with a severe and persistent delirium (defined as a DRS of 12 or more for more than 24 hours) were enrolled in the present study. In total 26 fulfilled these criteria of whom 17 were treated with orally administered rivastigmine with a total dose between 3 and 12 mg a day. Eight patients could not be treated because of dysphagia and one because of early discharge. Results: No major side effects were recorded. In 16 patients there was a considerable decrease in severity of delirium. The mean DRS declined from 14.8 on day one to 8.5 after therapy and 5.6 after tapering. The mean duration of delirium was 6.7 days (range; 2-17). Conclusion: Rivastigmine is safe in stroke patients with delirium even after rapid titration. In the majority of patients the delirium improved after treatment. A randomized controlled trial is needed to establish the usefulness of rivastigmine in delirium after stroke. Trial registration: Nederlands Trial Register NTR1395 [ABSTRACT FROM AUTHOR]

Published
2008

26. Variation in monitoring and treatment policies for intracranial hypertension in traumatic brain injury

Author

Cnossen, Maryse C., Huijben, Jilske A., van der Jagt, Mathieu, Volovici, Victor, van Essen, Thomas, Polinder, Suzanne, Nelson, David, Ercole, Ari, Stocchetti, Nino, Citerio, Giuseppe, Peul, Wilco C., Maas, Andrew I. R., Menon, David, Steyerberg, Ewout W., Lingsma, Hester F., Adams, Hadie, Alessandro, Masala, Allanson, Judith, Amrein, Krisztina, Andaluz, Norberto, Andelic, Nada, Andrea, Nanni, Andreassen, Lasse, Anke, Audny, Antoni, Anna, Ardon, Hilko, Audibert, Gérard, Auslands, Kaspars, Azouvi, Philippe, Baciu, Camelia, Bacon, Andrew, Badenes, Rafael, Baglin, Trevor, Bartels, Ronald, Barzó, Pál, Bauerfeind, Ursula, Beer, Ronny, Belda, Francisco Javier, Bellander, Bo-Michael, Belli, Antonio, Bellier, Rémy, Benali, Habib, Benard, Thierry, Berardino, Maurizio, Beretta, Luigi, Beynon, Christopher, Bilotta, Federico, Binder, Harald, Biqiri, Erta, Blaabjerg, Morten, Lund, Stine Borgen, Bouzat, Pierre, Bragge, Peter, Brazinova, Alexandra, Brehar, Felix, Brorsson, Camilla, Buki, Andras, Bullinger, Monika, Bucková, Veronika, Calappi, Emiliana, Cameron, Peter, Carbayo, Lozano Guillermo, Carise, Elsa, Carpenter, Keri, Castaño-León, Ana M., Causin, Francesco, Chevallard, Giorgio, Chieregato, Arturo, Cooper, M., Coburn, Mark, Coles, Jonathan, Cooper, Jamie D., Correia, Marta, Covic, Amra, Curry, Nicola, Czeiter, Endre, Czosnyka, Marek, Dahyot-Fizelier, Claire, Damas, François, Damas, Pierre, Dawes, Helen, De Keyser, Véronique, Corte, Francesco Della, Depreitere, Bart, Ding, Shenghao, Dippel, Diederik, Dizdarevic, Kemal, Dulière, Guy-Loup, Dzeko, Adelaida, Eapen, George, Engemann, Heiko, Esser, Patrick, Ezer, Erzsébet, Fabricius, Martin, Feigin, Valery L., Feng, Junfeng, Foks, Kelly, Fossi, Francesca, Francony, Gilles, Frantzén, Janek, Freo, Ulderico, Frisvold, Shirin, Furmanov, Alex, Gagliardo, Pablo, Galanaud, Damien, Gao, Guoyi, Geleijns, Karin, Ghuysen, Alexandre, Giraud, Benoit, Glocker, Ben, Gomez, Pedro A., Grossi, Francesca, Gruen, Russell L., Gupta, Deepak, Haagsma, Juanita A., Hadzic, Ermin, Haitsma, Iain, Hartings, Jed A., Helbok, Raimund, Helseth, Eirik, Hertle, Daniel, Hill, Sean, Hoedemaekers, Astrid, Hoefer, Stefan, Hutchinson, Peter J., Håberg, Kristine Asta, Jacobs, Bram, Janciak, Ivan, Janssens, Koen, Jiang, Ji-Yao, Jones, Kelly, Kalala, Jean-Pierre, Kamnitsas, Konstantinos, Karan, Mladen, Karau, Jana, Katila, Ari, Kaukonen, Maija, Keeling, David, Kerforne, Thomas, Ketharanathan, Naomi, Kettunen, Johannes, Kivisaari, Riku, Kolias, Angelos G., Kolumbán, Bálint, Kompanje, Erwin, Kondziella, Daniel, Koskinen, Lars-Owe, Kovács, Noémi, Kálovits, Ferenc, Lagares, Alfonso, Lanyon, Linda, Laureys, Steven, Lauritzen, Martin, Lecky, Fiona, Ledig, Christian, Lefering, Rolf, Legrand, Valerie, Lei, Jin, Levi, Leon, Lightfoot, Roger, Loeckx, Dirk, Lozano, Angels, Luddington, Roger, Luijten-Arts, Chantal, Macdonald, Stephen, Macfayden, Charles, Maegele, Marc, Majdan, Marek, Major, Sebastian, Manara, Alex, Manhes, Pauline, Manley, Geoffrey, Martin, Didier, Martino, Costanza, Maruenda, Armando, Maréchal, Hugues, Mastelova, Dagmara, Mattern, Julia, Mcmahon, Catherine, Melegh, Béla, Menovsky, Tomas, Morganti-Kossmann, Cristina, Mulazzi, Davide, Mutschler, Manuel, Mühlan, Holger, Negru, Ancuta, Neugebauer, Eddy, Newcombe, Virginia, Noirhomme, Quentin, Nyirádi, József, Oddo, Mauro, Oldenbeuving, Annemarie, Oresic, Matej, Ortolano, Fabrizio, Palotie, Aarno, Parizel, Paul M., Patruno, Adriana, Payen, Jean-François, Perera, Natascha, Perlbarg, Vincent, Persona, Paolo, Pichon, Nicolas, Piilgaard, Henning, Piippo, Anna, Floury, Sébastien Pili, Pirinen, Matti, Ples, Horia, Pomposo, Inigo, Psota, Marek, Pullens, Pim, Puybasset, Louis, Ragauskas, Arminas, Raj, Rahul, Rambadagalla, Malinka, Rehorcíková, Veronika, Rhodes, Jonathan, Richardson, Sylvia, Ripatti, Samuli, Rocka, Saulius, Rodier, Nicolas, Roe, Cecilie, Roise, Olav, Roks, Gerwin, Romegoux, Pauline, Rosand, Jonathan, Rosenfeld, Jeffrey, Rosenlund, Christina, Rosenthal, Guy, Rossaint, Rolf, Rossi, Sandra, Rostalski, Tim, Rueckert, Daniel, de Ruiz, Arcaute Felix, Rusnák, Martin, Sacchi, Marco, Sahakian, Barbara, Sahuquillo, Juan, Sakowitz, Oliver, Sala, Francesca, Sanchez-Pena, Paola, Sanchez-Porras, Renan, Sandor, Janos, Santos, Edgar, Sasse, Nadine, Sasu, Luminita, Savo, Davide, Schipper, Inger, Schlößer, Barbara, Schmidt, Silke, Schneider, Annette, Schoechl, Herbert, Schoonman, Guus, Rico, Frederik Schou, Schwendenwein, Elisabeth, Schöll, Michael, Sir, Özcan, Skandsen, Toril, Smakman, Lidwien, Smeets, Dirk, Smielewski, Peter, Sorinola, Abayomi, Stamatakis, Emmanuel, Stanworth, Simon, Stegemann, Katrin, Steinbüchel, Nicole, Stevens, Robert, Stewart, William, Sundström, Nina, Synnot, Anneliese, Szabó, József, Söderberg, Jeannette, Taccone, Fabio Silvio, Tamás, Viktória, Tanskanen, Päivi, Tascu, Alexandru, Taylor, Mark Steven, Ao Braden, Te, Tenovuo, Olli, Teodorani, Guido, Theadom, Alice, Thomas, Matt, Tibboel, Dick, Tolias, Christos, Tshibanda, Jean-Flory Luaba, Tudora, Cristina Maria, Vajkoczy, Peter, Valeinis, Egils, Hecke, Wim Van, Praag, Dominique Van, Dirk, Van Roost, Vlierberghe, Eline Van, Vyvere, Thijs vande, Vanhaudenhuyse, Audrey, Vargiolu, Alessia, Vega, Emmanuel, Verheyden, Jan, Vespa, Paul M., Vik, Anne, Vilcinis, Rimantas, Vizzino, Giacinta, Vleggeert-Lankamp, Carmen, Vulekovic, Peter, Vámos, Zoltán, Wade, Derick, Wang, Kevin K. W., Wang, Lei, Wildschut, Eno, Williams, Guy, Willumsen, Lisette, Wilson, Adam, Wilson, Lindsay, Winkler, Maren K. L., Ylén, Peter, Younsi, Alexander, Zaaroor, Menashe, Zhang, Zhiqun, Zheng, Zelong, Zumbo, Fabrizio, de Lange, Stefanie, de Ruiter, Godard C. W., den Boogert, Hugo, van Dijck, Jeroen, van Heugten, Caroline, van der Naalt, Joukje, Cnossen, Maryse C., Huijben, Jilske A., Van der Jagt, Mathieu, Volovici, Victor, Van Essen, Thoma, Polinder, Suzanne, Nelson, David, Ercole, Ari, Stocchetti, Nino, Citerio, Giuseppe, Peul, Wilco C., Maas, Andrew I. R., Menon, David, Steyerberg, Ewout W., Lingsma, Hester F., on behalf of the CENTER-TBI, Investigator, Beretta, Luigi, Cnossen, M, Huijben, J, van der Jagt, M, Volovici, V, van Essen, T, Polinder, S, Nelson, D, Ercole, A, Stocchetti, N, Citerio, G, Peul, W, Maas, A, Menon, D, Steyerberg, E, Lingsma, H, Molecular Neuroscience and Ageing Research (MOLAR), Psychiatrie & Neuropsychologie, RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, Commission of the European Communities, CENTER-TBI Investigators, Medical Informatics, Public and occupational health, Ragauskas, Arminas, Ročka, Saulius, Vilcinis, Rimantas, Public Health, Intensive Care, Neurosurgery, CENTER-TBI investigators, Adams, H., Alessandro, M., Allanson, J., Amrein, K., Andaluz, N., Andelic, N., Andrea, N., Andreassen, L., Anke, A., Antoni, A., Ardon, H., Audibert, G., Auslands, K., Azouvi, P., Baciu, C., Bacon, A., Badenes, R., Baglin, T., Bartels, R., Barzó, P., Bauerfeind, U., Beer, R., Belda, F.J., Bellander, B.M., Belli, A., Bellier, R., Benali, H., Benard, T., Berardino, M., Beretta, L., Beynon, C., Bilotta, F., Binder, H., Biqiri, E., Blaabjerg, M., Borgen, L.S., Bouzat, P., Bragge, P., Brazinova, A., Brehar, F., Brorsson, C., Buki, A., Bullinger, M., Bučková, V., Calappi, E., Cameron, P., Lozano, G.C., Carise, E., Carpenter, K., Castaño-León, A.M., Causin, F., Chevallard, G., Chieregato, A., Citerio, G., Cnossen, M., Coburn, M., Coles, J., Cooper, J.D., Correia, M., Covic, A., Curry, N., Czeiter, E., Czosnyka, M., Dahyot-Fizelier, C., Damas, F., Damas, P., Dawes, H., De Keyser, V., Corte, F.D., Depreitere, B., Ding, S., Dippel, D., Dizdarevic, K., Dulière, G.L., Dzeko, A., Eapen, G., Engemann, H., Ercole, A., Esser, P., Ezer, E., Fabricius, M., Feigin, V.L., Feng, J., Foks, K., Fossi, F., Francony, G., Frantzén, J., Freo, U., Frisvold, S., Furmanov, A., Gagliardo, P., Galanaud, D., Gao, G., Geleijns, K., Ghuysen, A., Giraud, B., Glocker, B., Gomez, P.A., Grossi, F., Gruen, R.L., Gupta, D., Haagsma, J.A., Hadzic, E., Haitsma, I., Hartings, J.A., Helbok, R., Helseth, E., Hertle, D., Hill, S., Hoedemaekers, A., Hoefer, S., Hutchinson, P.J., Håberg, A.K., Jacobs, B., Janciak, I., Janssens, K., Jiang, J.Y., Jones, K., Kalala, J.P., Kamnitsas, K., Karan, M., Karau, J., Katila, A., Kaukonen, M., Keeling, D., Kerforne, T., Ketharanathan, N., Kettunen, J., Kivisaari, R., Kolias, A.G., Kolumbán, B., Kompanje, E., Kondziella, D., Koskinen, L.O., Kovács, N., Kálovits, F., Lagares, A., Lanyon, L., Laureys, S., Lauritzen, M., Lecky, F., Ledig, C., Lefering, R., Legrand, V., Lei, J., Levi, L., Lightfoot, R., Lingsma, H., Loeckx, D., Lozano, A., Luddington, R., Luijten-Arts, C., Andrew, IRM, MacDonald, S., MacFayden, C., Maegele, M., Majdan, M., Major, S., Manara, A., Manhes, P., Manley, G., Martin, D., Martino, C., Maruenda, A., Maréchal, H., Mastelova, D., Mattern, J., McMahon, C., Melegh, B., Menon, D., Menovsky, T., Morganti-Kossmann, C., Mulazzi, D., Mutschler, M., Mühlan, H., Negru, A., Nelson, D., Neugebauer, E., Newcombe, V., Noirhomme, Q., Nyirádi, J., Oddo, M., Oldenbeuving, A., Oresic, M., Ortolano, F., Palotie, A., Parizel, P.M., Patruno, A., Payen, J.F., Perera, N., Perlbarg, V., Persona, P., Peul, W., Pichon, N., Piilgaard, H., Piippo, A., Floury, S.P., Pirinen, M., Ples, H., Polinder, S., Pomposo, I., Psota, M., Pullens, P., Puybasset, L., Ragauskas, A., Raj, R., Rambadagalla, M., Rehorčíková, V., Rhodes, J., Richardson, S., Ripatti, S., Rocka, S., Rodier, N., Roe, C., Roise, O., Roks, G., Romegoux, P., Rosand, J., Rosenfeld, J., Rosenlund, C., Rosenthal, G., Rossaint, R., Rossi, S., Rostalski, T., Rueckert, D., de Arcaute, F.R., Rusnák, M., Sacchi, M., Sahakian, B., Sahuquillo, J., Sakowitz, O., Sala, F., Sanchez-Pena, P., Sanchez-Porras, R., Sandor, J., Santos, E., Sasse, N., Sasu, L., Savo, D., Schipper, I., Schlößer, B., Schmidt, S., Schneider, A., Schoechl, H., Schoonman, G., Schou, R.F., Schwendenwein, E., Schöll, M., Sir, Ö., Skandsen, T., Smakman, L., Smeets, D., Smielewski, P., Sorinola, A., Stamatakis, E., Stanworth, S., Stegemann, K., Steinbüchel, N., Stevens, R., Stewart, W., Steyerberg, E.W., Stocchetti, N., Sundström, N., Synnot, A., Szabó, J., Söderberg, J., Taccone, F.S., Tamás, V., Tanskanen, P., Tascu, A., Taylor, M.S., Te Ao, B., Tenovuo, O., Teodorani, G., Theadom, A., Thomas, M., Tibboel, D., Tolias, C., Tshibanda, J.L., Tudora, C.M., Vajkoczy, P., Valeinis, E., Van Hecke, W., Van Praag, D., Van Roost, D., Van Vlierberghe, E., Vyvere, T.V., Vanhaudenhuyse, A., Vargiolu, A., Vega, E., Verheyden, J., Vespa, P.M., Vik, A., Vilcinis, R., Vizzino, G., Vleggeert-Lankamp, C., Volovici, V., Vulekovic, P., Vámos, Z., Wade, D., Wang, KKW, Wang, L., Wildschut, E., Williams, G., Willumsen, L., Wilson, A., Wilson, L., Winkler, MKL, Ylén, P., Younsi, A., Zaaroor, M., Zhang, Z., Zheng, Z., Zumbo, F., de Lange, S., de Ruiter, GCW, den Boogert, H., van Dijck, J., van Essen, T.A., van Heugten, C., van der Jagt, M., van der Naalt, J., Rocka, Saulius, „Springer' grupė, Apollo - University of Cambridge Repository, Centre of Excellence in Complex Disease Genetics, Department of Mathematics and Statistics, Institute for Molecular Medicine Finland, Biostatistics Helsinki, Aarno Palotie / Principal Investigator, University of Helsinki, Neurokirurgian yksikkö, Clinicum, Samuli Olli Ripatti / Principal Investigator, Complex Disease Genetics, Genomics of Neurological and Neuropsychiatric Disorders, and Statistical and population genetics

Subjects
Neurology, Letter, IMPACT, Critical Care and Intensive Care Medicine, Intracranial hypertension, 0302 clinical medicine, Traumatic brain injury, Clinical Protocols, Trauma Centers, Surveys and Questionnaires, Brain Injuries, Traumatic, Medicine and Health Sciences, Longitudinal Studies, Prospective Studies, Prospective cohort study, Comparative effectiveness research, Survey, Comparative, effectiveness research, Intracranial pressure, Response rate (survey), Medicine (all), Head injury, lcsh:Medical emergencies. Critical care. Intensive care. First aid, 11 Medical And Health Sciences, Orvostudományok, 3. Good health, Europe, Neurosurgery, medicine.medical_specialty, Critical Care, Other Research Radboud Institute for Molecular Life Sciences [Radboudumc 0], PRESSURE, Klinikai orvostudományok, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18], 03 medical and health sciences, ICP, ICU, medicine, MANAGEMENT, Humans, Monitoring, Physiologic, business.industry, MORTALITY, Research, 3112 Neurosciences, HEAD-INJURY, 030208 emergency & critical care medicine, lcsh:RC86-88.9, CARE, medicine.disease, Emergency & Critical Care Medicine, nervous system diseases, traumatic brain injury, comparative effectiveness research, survey, Emergency medicine, Physical therapy, Dentistry (all), MODERATE, Human medicine, business, 030217 neurology & neurosurgery, EUROPEAN-BRAIN
Abstract

Background No definitive evidence exists on how intracranial hypertension should be treated in patients with traumatic brain injury (TBI). It is therefore likely that centers and practitioners individually balance potential benefits and risks of different intracranial pressure (ICP) management strategies, resulting in practice variation. The aim of this study was to examine variation in monitoring and treatment policies for intracranial hypertension in patients with TBI. Methods A 29-item survey on ICP monitoring and treatment was developed on the basis of literature and expert opinion, and it was pilot-tested in 16 centers. The questionnaire was sent to 68 neurotrauma centers participating in the Collaborative European Neurotrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) study. Results The survey was completed by 66 centers (97% response rate). Centers were mainly academic hospitals (n = 60, 91%) and designated level I trauma centers (n = 44, 67%). The Brain Trauma Foundation guidelines were used in 49 (74%) centers. Approximately 90% of the participants (n = 58) indicated placing an ICP monitor in patients with severe TBI and computed tomographic abnormalities. There was no consensus on other indications or on peri-insertion precautions. We found wide variation in the use of first- and second-tier treatments for elevated ICP. Approximately half of the centers were classified as using a relatively aggressive approach to ICP monitoring and treatment (n = 32, 48%), whereas the others were considered more conservative (n = 34, 52%). Conclusions Substantial variation was found regarding monitoring and treatment policies in patients with TBI and intracranial hypertension. The results of this survey indicate a lack of consensus between European neurotrauma centers and provide an opportunity and necessity for comparative effectiveness research. Electronic supplementary material The online version of this article (doi:10.1186/s13054-017-1816-9) contains supplementary material, which is available to authorized users.

Published
2017
Full Text
View/download PDF

27. Ultra-Early and Short-Term Tranexamic Acid Treatment in Patients With Good- and Poor-Grade Aneurysmal Subarachnoid Hemorrhage.

Author

Tjerkstra MA, Post R, Germans MR, Vergouwen MDI, Jellema K, Koot RW, Kruyt ND, Wolfs JFC, De Beer FC, Kieft HH, Nanda D, Van Der Pol B, Roks G, De Beer F, Reichman LJA, Brouwers PJAM, Kwa VIH, Van Der Ree TC, Bienfait HP, Boogaarts HD, Klijn CJ, Visser V, van den Berg R, Coert BA, Horn J, Majoie CBLM, Rinkel GJE, Roos YBWEM, Vandertop WP, and Verbaan D

Subjects
Humans, Female, Male, Middle Aged, Treatment Outcome, Aged, Prospective Studies, Adult, Tranexamic Acid therapeutic use, Tranexamic Acid administration & dosage, Subarachnoid Hemorrhage drug therapy, Antifibrinolytic Agents therapeutic use, Antifibrinolytic Agents administration & dosage
Abstract

Background and Objectives: The results of the ULTRA trial showed that ultra-early and short-term treatment with tranexamic acid (TXA) does not improve clinical outcome after aneurysmal subarachnoid hemorrhage (aSAH). Possibly, the lack of a beneficial effect in all patients with aSAH is masked by antagonistic effects of TXA in certain subgroups. In this post hoc subgroup analysis, we investigated the effect of TXA on clinical outcome in patients with good-grade and poor-grade aSAH., Methods: The ULTRA trial was a multicenter, prospective, randomized, controlled, open-label trial with blinded outcome assessment. Participants received ultra-early and short-term TXA in addition to usual care or usual care only. This post hoc subgroup analysis included only ULTRA participants with confirmed aSAH and available World Federation of Neurosurgical Societies (WFNS) grade on admission. Patients were categorized into those with good-grade (WFNS 1-3) and poor-grade (WFNS 4-5) aSAH. The primary outcome was clinical outcome assessed by the modified Rankin scale (mRS). Odds ratios (ORs) and adjusted ORs (aORs) with 95% CIs were calculated using ordinal regression analyses. Analyses were performed using the as-treated principle. In all patients with aSAH, no significant effect modification of TXA on clinical outcome was observed for admission WFNS grade ( p = 0.10)., Results: Of the 812 ULTRA participants, 473 patients had (58%; N = 232 TXA, N = 241 usual care) good-grade and 339 (42%; N = 162 TXA, N = 176 usual care) patients had poor-grade aSAH. In patients with good-grade aSAH, the TXA group had worse clinical outcomes (OR: 0.67, 95% CI 0.48-0.94, aOR 0.68, 95% CI 0.48-0.94) compared with the usual care group. In patients with poor-grade aSAH, clinical outcomes were comparable between treatment groups (OR: 1.04, 95% CI 0.70-1.55, aOR 1.05, 95% CI 0.70-1.56)., Discussion: This post hoc subgroup analysis provides another important argument against the use of TXA treatment in patients with aSAH, by showing worse clinical outcomes in patients with good-grade aSAH treated with TXA and no clinical benefit of TXA in patients with poor-grade aSAH, compared with patients treated with usual care., Trial Registration Information: ClinicalTrials.gov (NCT02684812; submission date February 18, 2016, first patient enrollment on July 24, 2013)., Classification of Evidence: This study provides Class II evidence that tranexamic acid, given for <24 hours within the first 24 hours, does not improve the 6-month outcome in good-grade or poor initial-grade aneurysmal SAH.

Published
2024
Full Text
View/download PDF

28. Motivations of patients and their care partners for visiting a memory clinic. A qualitative study.

Author

Visser LNC, Fruijtier A, Kunneman M, Bouwman FH, Schoonenboom N, Staekenborg SS, Wind HA, Hempenius L, de Beer MH, Roks G, Boelaarts L, Kleijer M, Smets EMA, and van der Flier WM

Subjects
Humans, Female, Middle Aged, Aged, Aged, 80 and over, Male, Referral and Consultation, Surveys and Questionnaires, Ambulatory Care Facilities, Motivation, Caregivers
Abstract

Objective: We investigated motivations of patients and care partners for their memory clinic visit, and whether these are expressed in consultations., Methods: We included data from 115 patients (age 71 ± 11, 49% Female) and their care partners (N = 93), who completed questionnaires after their first consultation with a clinician. Audio-recordings of these consultations were available from 105 patients. Motivations for visiting the clinic were content-coded as reported by patients in the questionnaire, and expressed by patients and care partners in consultations., Results: Most patients reported seeking a cause for symptoms (61%) or to confirm/exclude a (dementia) diagnosis (16%), yet 19% reported another motivation: (more) information, care access, or treatment/advice. In the first consultation, about half of patients (52%) and care partners (62%) did not express their motivation(s). When both expressed a motivation, these differed in about half of dyads. A quarter of patients (23%) expressed a different/complementary motivation in the consultation, then reported in the questionnaire., Conclusion: Motivations for visiting a memory clinic can be specific and multifaceted, yet are often not addressed during consultations., Practice Implications: We should encourage clinicians, patients, and care partners to talk about motivations for visiting the memory clinic, as a starting point to personalize (diagnostic) care., Competing Interests: Conflicts of interest Research programs of Wiesje van der Flier (WvdF) have been funded by ZonMW, NWO, EU-FP7, EU-JPND, Alzheimer Nederland, Hersenstichting CardioVascular Onderzoek Nederland, Health∼Holland, Topsector Life Sciences & Health, stichting Dioraphte, Gieskes-Strijbis fonds, stichting Equilibrio, Edwin Bouw fonds, Pasman stichting, stichting Alzheimer & Neuropsychiatrie Foundation, Philips, Biogen MA Inc, Novartis-NL, Life-MI, AVID, Roche BV, Fujifilm, and Combinostics. WF has performed contract research for Biogen MA Inc and Boehringer Ingelheim, and has been an invited speaker at Boehringer Ingelheim, Biogen MA Inc, Danone, Eisai, WebMD Neurology (Medscape), and Springer Healthcare. All funding is paid to her institution. Leonie Visser (LNCV) has been an invited speaker at Schwabe Group, fees were paid to her institution. All other authors declare no conflicts of interest., (Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.)

Published
2023
Full Text
View/download PDF

29. Tranexamic Acid After Aneurysmal Subarachnoid Hemorrhage: Post Hoc Analysis of the ULTRA Trial.

Author

Tjerkstra MA, Post R, Germans MR, Vergouwen MDI, Jellema K, Koot RW, Kruyt ND, Willems PWA, Wolfs JFC, de Beer FC, Kieft H, Nanda D, van der Pol B, Roks G, de Beer F, Halkes PHA, Reichman LJA, Brouwers PJAM, Van den Berg-Vos RM, Kwa VIH, van der Ree TC, Bronner I, Bienfait HP, Boogaarts H, Klijn CJM, van den Berg R, Coert BA, Horn J, Majoie CBLM, Rinkel GJE, Roos YBWM, Vandertop WP, and Verbaan D

Subjects
Humans, Prospective Studies, Treatment Outcome, Outcome Assessment, Health Care, Tranexamic Acid therapeutic use, Subarachnoid Hemorrhage complications, Subarachnoid Hemorrhage diagnostic imaging, Subarachnoid Hemorrhage drug therapy
Abstract

Background and Objectives: The ULTRA trial showed that ultra-early and short-term tranexamic acid treatment after subarachnoid hemorrhage did not improve clinical outcome at 6 months. An expected proportion of the included patients experienced nonaneurysmal subarachnoid hemorrhage. In this post hoc study, we will investigate whether ultra-early and short-term tranexamic acid treatment in patients with aneurysmal subarachnoid hemorrhage improves clinical outcome at 6 months., Methods: The ULTRA trial is a multicenter, prospective, randomized, controlled, open-label trial with blinded outcome assessment, conducted between July 24, 2013, and January 20, 2020. After confirmation of subarachnoid hemorrhage on noncontrast CT, patients were allocated to either ultra-early and short-term tranexamic acid treatment with usual care or usual care only. In this post hoc analysis, we included all ULTRA participants with a confirmed aneurysm on CT angiography and/or digital subtraction angiography. The primary endpoint was clinical outcome at 6 months, assessed by the modified Rankin scale (mRS), dichotomized into good (0-3) and poor (4-6) outcomes., Results: Of the 813 ULTRA trial patients who experienced an aneurysmal subarachnoid hemorrhage, 409 (50%) were assigned to the tranexamic acid group and 404 (50%) to the control group. In the intention-to-treat analysis, 233 of 405 (58%) patients in the tranexamic acid group and 238 of 399 (60%) patients in the control group had a good clinical outcome (adjusted odds ratio [aOR] 0.92; 95% CI 0.69-1.24). None of the secondary outcomes showed significant differences between the treatment groups: excellent clinical outcome (mRS 0-2) (aOR 0.76; 95% CI 0.57-1.03), all-cause mortality at 30 days (aOR 0.91; 95% CI 0.65-1.28), and all-cause mortality at 6 months (aOR 1.10; 95% CI 0.80-1.52)., Discussion: Ultra-early and short-term tranexamic acid treatment did not improve clinical outcomes at 6 months in patients with aneurysmal subarachnoid hemorrhage and therefore cannot be recommended., Trial Registration Information: ClinicalTrials.gov (NCT02684812; submission date February 18, 2016, first patient enrollment on July 24, 2013)., Classification of Evidence: This study provides Class II evidence that tranexamic acid does not improve outcomes in patients presenting with aneurysmal subarachnoid hemorrhage., (© 2022 American Academy of Neurology.)

Published
2022
Full Text
View/download PDF

30. C-Terminal Proarginine Vasopressin is Associated with Disease Outcome and Mortality, but not with Delayed Cerebral Ischemia in Critically Ill Patients with an Aneurysmal Subarachnoid Hemorrhage: A Prospective Cohort Study.

Author

van Oers JAH, Ramnarain D, Oldenbeuving A, Vos P, Roks G, Kluiters Y, Beishuizen A, de Lange DW, de Grooth HJ, and Girbes ARJ

Subjects
Humans, Prospective Studies, Critical Illness, Cerebral Infarction complications, Cohort Studies, Vasopressins, Subarachnoid Hemorrhage complications, Brain Ischemia complications
Abstract

Background: Aneurysmal subarachnoid hemorrhage (aSAH) is an important indication for intensive care unit admission and may lead to significant morbidity and mortality. We assessed the ability of C-terminal proarginine vasopressin (CT-proAVP) to predict disease outcome, mortality, and delayed cerebral ischemia (DCI) in critically ill patients with aSAH compared with the World Federation of Neurological Surgeons (WFNS) score and Acute Physiological and Chronic Health Evaluation IV (APACHE IV) model., Methods: C-terminal proarginine vasopressin was collected on admission in this single-center, prospective, observational cohort study. The primary aim was to investigate the relationship between CT-proAVP and poor functional outcome at 1 year (Glasgow Outcome Scale score 1-3) in a multivariable logistic regression model adjusted for WFNS and APACHE IV scores. Secondary aims were mortality and DCI. The multivariable logistic regression model for DCI was also adjusted for the modified Fisher scale., Results: In 100 patients, the median CT-proAVP level was 24.9 pmol/L (interquartile range 11.5-53.8); 45 patients had a poor 1-year functional outcome, 19 patients died within 30 days, 25 patients died within 1 year, and DCI occurred in 28 patients. Receiver operating characteristics curves revealed high accuracy for CT-proAVP to identify patients with poor 1-year functional outcome (area under the curve [AUC] 0.84, 95% confidence interval [CI] 0.77-0.92, p < 0.001), 30-day mortality (AUC 0.84, 95% CI 0.76-0.93, p < 0.001), and 1-year mortality (AUC 0.79, 95% CI 0.69-0.89, p < 0.001). CT-proAVP had a low AUC for identifying patients with DCI (AUC 0.67, 95% CI 0.55-0.79, p 0.008). CT-proAVP ≥ 24.9 pmo/L proved to be a significant predictor for poor 1-year functional outcome (odds ratio [OR] 8.04, 95% CI 2.97-21.75, p < 0.001), and CT-proAVP ≥ 29.1 pmol/L and ≥ 27.7 pmol/L were significant predictors for 30-day and 1-year mortality (OR 9.31, 95% CI 1.55-56.07, p 0.015 and OR 5.15, 95% CI 1.48-17.93, p 0.010) in multivariable models with WFNS and APACHE IV scores. CT-proAVP ≥ 29.5 pmol/L was not a significant predictor for DCI in a multivariable model adjusted for the modified Fisher scale (p = 0.061)., Conclusions: C-terminal proarginine vasopressin was able to predict poor functional outcome and mortality in critically ill patients with aSAH. Its prognostic ability to predict DCI was low., Trial Registration: Nederlands Trial Register: NTR4118., (© 2022. The Author(s).)

Published
2022
Full Text
View/download PDF

31. Clinical applicability of quantitative atrophy measures on MRI in patients suspected of Alzheimer's disease.

Author

Ingala S, van Maurik IS, Altomare D, Wurm R, Dicks E, van Schijndel RA, Zwan M, Bouwman F, Schoonenboom N, Boelaarts L, Roks G, van Marum R, van Harten B, van Uden I, Claus J, Wottschel V, Vrenken H, Wattjes MP, van der Flier WM, and Barkhof F

Subjects
Female, Humans, Middle Aged, Aged, Male, Atrophy, Magnetic Resonance Imaging methods, Alzheimer Disease diagnosis, Cognitive Dysfunction pathology, Hepatitis C
Abstract

Objectives: Neurodegeneration in suspected Alzheimer's disease can be determined using visual rating or quantitative volumetric assessments. We examined the feasibility of volumetric measurements of gray matter (GMV) and hippocampal volume (HCV) and compared their diagnostic performance with visual rating scales in academic and non-academic memory clinics., Materials and Methods: We included 231 patients attending local memory clinics (LMC) in the Netherlands and 501 of the academic Amsterdam Dementia Cohort (ADC). MRI scans were acquired using local protocols, including a T1-weighted sequence. Quantification of GMV and HCV was performed using FSL and FreeSurfer. Medial temporal atrophy and global atrophy were assessed with visual rating scales. ROC curves were derived to determine which measure discriminated best between cognitively normal (CN), mild cognitive impairment (MCI), and Alzheimer's dementia (AD)., Results: Patients attending LMC (age 70.9 ± 8.9 years; 47% females; 19% CN; 34% MCI; 47% AD) were older, had more cerebrovascular pathology, and had lower GMV and HCV compared to those of the ADC (age 64.9 ± 8.2 years; 42% females; 35% CN, 43% MCI, 22% AD). While visual ratings were feasible in > 95% of scans in both cohorts, quantification was achieved in 94-98% of ADC, but only 68-85% of LMC scans, depending on the software. Visual ratings and volumetric outcomes performed similarly in discriminating CN vs AD in both cohorts., Conclusion: In clinical settings, quantification of GM and hippocampal atrophy currently fails in up to one-third of scans, probably due to lack of standardized acquisition protocols. Diagnostic accuracy is similar for volumetric measures and visual rating scales, making the latter suited for clinical practice. In a real-life clinical setting, volumetric assessment of MRI scans in dementia patients may require acquisition protocol optimization and does not outperform visual rating scales., Key Points: • In a real-life clinical setting, the diagnostic performance of visual rating scales is similar to that of automatic volumetric quantification and may be sufficient to distinguish Alzheimer's disease groups. • Volumetric assessment of gray matter and hippocampal volumes from MRI scans of patients attending non-academic memory clinics fails in up to 32% of cases. • Clinical MR acquisition protocols should be optimized to improve the output of quantitative software for segmentation of Alzheimer's disease-specific outcomes., (© 2022. The Author(s).)

Published
2022
Full Text
View/download PDF

32. Poor outcome in frail elderly patient after severe TBI.

Author

Herklots MW, Kroon M, Roks G, Oldenbeuving A, and Schoonman GG

Subjects
Aged, Frail Elderly, Glasgow Coma Scale, Glasgow Outcome Scale, Humans, Retrospective Studies, Brain Injuries, Traumatic, Frailty
Abstract

Objective: To investigate the influence of frailty in elderly with severe TBI on mortality and functional outcome., Method: 126 patients with TBI aged 60 years or older and with a presenting Glasgow Coma Scale score of 8 or lower were retrospectively included. To investigate frailty, we used the CSHA Clinical Frailty Scale. The primary outcome measures were mortality, and the secondary outcome measures were Glasgow Outcome Scale Extended (GOSE) at discharge and GOSE at 6 months after trauma., Results: High frailty was a significant predictor for mortality (OR 2.38, p 0.047), if adjusted for the injury severity scale. High frailty was also a significant predictor for poor functional outcome after 6 months (OR 4.35, p 0.03). After 6 months, the GOSE of the low frailty group was significantly higher than in the high frailty group (p 0.019). Also, the improvement of the GOSE was significant in the low frailty group (p 0.007), while in the high frailty group there was no significant improvement of the GOSE (p 0.546) after 6 months., Conclusion: Frailty has a significant impact on outcome in elderly with severe TBI. There is a higher mortality in the frail elderly and there is less recovery after TBI.

Published
2022
Full Text
View/download PDF

33. Ultra-early tranexamic acid after subarachnoid haemorrhage (ULTRA): a randomised controlled trial.

Author

Post R, Germans MR, Tjerkstra MA, Vergouwen MDI, Jellema K, Koot RW, Kruyt ND, Willems PWA, Wolfs JFC, de Beer FC, Kieft H, Nanda D, van der Pol B, Roks G, de Beer F, Halkes PHA, Reichman LJA, Brouwers PJAM, van den Berg-Vos RM, Kwa VIH, van der Ree TC, Bronner I, van de Vlekkert J, Bienfait HP, Boogaarts HD, Klijn CJM, van den Berg R, Coert BA, Horn J, Majoie CBLM, Rinkel GJE, Roos YBWEM, Vandertop WP, and Verbaan D

Subjects
Aged, Female, Humans, Male, Middle Aged, Netherlands, Prospective Studies, Subarachnoid Hemorrhage mortality, Time Factors, Treatment Outcome, Antifibrinolytic Agents administration & dosage, Subarachnoid Hemorrhage drug therapy, Tranexamic Acid administration & dosage
Abstract

Background: In patients with aneurysmal subarachnoid haemorrhage, short-term antifibrinolytic therapy with tranexamic acid has been shown to reduce the risk of rebleeding. However, whether this treatment improves clinical outcome is unclear. We investigated whether ultra-early, short-term treatment with tranexamic acid improves clinical outcome at 6 months., Methods: In this multicentre prospective, randomised, controlled, open-label trial with masked outcome assessment, adult patients with spontaneous CT-proven subarachnoid haemorrhage in eight treatment centres and 16 referring hospitals in the Netherlands were randomly assigned to treatment with tranexamic acid in addition to care as usual (tranexamic acid group) or care as usual only (control group). Tranexamic acid was started immediately after diagnosis in the presenting hospital (1 g bolus, followed by continuous infusion of 1 g every 8 h, terminated immediately before aneurysm treatment, or 24 h after start of the medication, whichever came first). The primary endpoint was clinical outcome at 6 months, assessed by the modified Rankin Scale, dichotomised into a good (0-3) or poor (4-6) clinical outcome. Both primary and safety analyses were according to intention to treat. This trial is registered at ClinicalTrials.gov, NCT02684812., Findings: Between July 24, 2013, and July 29, 2019, we enrolled 955 patients; 480 patients were randomly assigned to tranexamic acid and 475 patients to the control group. In the intention-to-treat analysis, good clinical outcome was observed in 287 (60%) of 475 patients in the tranexamic acid group, and 300 (64%) of 470 patients in the control group (treatment centre adjusted odds ratio 0·86, 95% CI 0·66-1·12). Rebleeding after randomisation and before aneurysm treatment occurred in 49 (10%) patients in the tranexamic acid and in 66 (14%) patients in the control group (odds ratio 0·71, 95% CI 0·48-1·04). Other serious adverse events were comparable between groups., Interpretation: In patients with CT-proven subarachnoid haemorrhage, presumably caused by a ruptured aneurysm, ultra-early, short-term tranexamic acid treatment did not improve clinical outcome at 6 months, as measured by the modified Rankin Scale., Funding: Fonds NutsOhra., (Copyright © 2021 Elsevier Ltd. All rights reserved.)

Published
2021
Full Text
View/download PDF

34. What patients want to know, and what we actually tell them: The ABIDE project.

Author

Fruijtier AD, Visser LNC, Bouwman FH, Lutz R, Schoonenboom N, Kalisvaart K, Hempenius L, Roks G, Boelaarts L, Claus JJ, Kleijer M, de Beer M, van der Flier WM, and Smets EMA

Abstract

Background: We studied to what degree and at whose initiative 25 informational topics, formerly identified as important, are discussed in diagnostic consultations., Methods: Audio recordings of clinician-patient consultations of 71 patients and 32 clinicians, collected in eight Dutch memory clinics, were independently content-coded by two coders. The coding scheme encompassed 25 informational topics., Results: Approximately half ( Mdn  = 12) of the 25 topics were discussed per patient during the diagnostic process, with a higher frequency among individuals receiving a dementia diagnosis ( Mdn  = 14) compared to others ( Mdn  = 11). Individual topics ranged from being discussed with 2/71 (3%) to 70/71 (99%) of patients. Patients and/or care partners rarely initiated topic discussion (10%). When they did, they often enquired about one of the least frequently addressed topics., Conclusion: Most patients received information on approximately half of the important informational topics. Providing the topic list to patients and care partners beforehand could allow consultation preparation and stimulate participation., Competing Interests: The authors have declared no conflicts of interest for this article. The funding sources had no involvement in the study design; data collection, analysis, and interpretation; in writing the article; nor in the decision to submit this article for publication., (© 2020 The Authors. Alzheimer's & Dementia: Translational Research & Clinical Interventions published by Wiley Periodicals, Inc. on behalf of Alzheimer's Association.)

Published
2020
Full Text
View/download PDF

35. Patients with mild traumatic brain injury and acute neck pain at the emergency department are a distinct category within the mTBI spectrum: a prospective multicentre cohort study.

Author

Coffeng SM, Jacobs B, de Koning ME, Hageman G, Roks G, and van der Naalt J

Subjects
Adult, Cohort Studies, Female, Follow-Up Studies, Glasgow Outcome Scale, Humans, Male, Middle Aged, Prospective Studies, Risk Factors, Surveys and Questionnaires, Young Adult, Brain Concussion complications, Emergency Service, Hospital, Neck Pain etiology
Abstract

Background: Acute neck pain (ANP) has recently been demonstrated to be a predictor of persistent posttraumatic complaints after mild traumatic brain injury (mTBI). The aim of this study was to determine specific characteristics of patients with ANP following mTBI, their posttraumatic complaints and relationship with functional outcome., Methods: Data from a prospective follow-up study of 922 mTBI patients admitted to the emergency department (ED) in three level-one trauma centres were analysed. Patients were divided into two groups: 156 ANP patients and 766 no acute neck pain (nANP) patients. Posttraumatic complaints were evaluated 2 weeks and 6 months post-injury using standardized questionnaires and functional outcome was evaluated at 6 months with the Glasgow Outcome Scale Extended (GOSE)., Results: ANP patients were more often female (p < 0.01), younger (38 vs. 47 years, p < 0.01) with more associated acute symptoms at the ED (p < 0.05) compared to nANP patients. More motor vehicle accidents (12% vs. 6%, p = 0.01) and less head wounds (58% vs. 73%, p < 0.01) in ANP patients indicated 'high-energy low-impact' trauma mechanisms. ANP patients showed more posttraumatic complaints 2 weeks and 6 months post-injury (p < 0.05) and more often incomplete recovery (GOSE < 8) was present after 6 months (56% vs. 40%, p = 0.01)., Conclusions: MTBI patients with acute neck pain at the ED constitute a distinct group within the mTBI spectrum with specific injury and demographic characteristics. Early identification of this at risk group already at the ED might allow specific and timely treatment to avoid development of incomplete recovery.

Published
2020
Full Text
View/download PDF

36. Accuracy in prediction of long-term functional outcome in patients with traumatic axonal injury: a comparison of MRI scales.

Author

van Eijck MM, Herklots MW, Peluso J, Schoonman GG, Oldenbeuving AW, de Vries J, van der Naalt J, and Roks G

Subjects
Axons, Humans, Magnetic Resonance Imaging, Retrospective Studies, Brain Injuries, Traumatic diagnostic imaging, Diffuse Axonal Injury diagnostic imaging
Abstract

Purpose : Functional outcome prediction for patients with traumatic axonal injury (TAI) is not highly related to the MRI classifications. The aim of this study was to assess the accuracy in predicting functional outcome in patients with TAI with several MRI scoring methods and to define the most accurate method. Methods : Patients with TAI (2008-2014) confirmed on MRI <6 months after injury were included in this retrospective study. Long-term functional outcome was prospectively assessed using the Glasgow Outcome Score Extended. The Gentry classification is most used in clinical practice. This method was compared to methods that score lesion load, lesion locations, and to modified Gentry classifications. The area under the curve (AUC) was calculated for the scoring methods. Results : A total of 124 patients with TAI were included, medium follow-up 52 months. The AUC for the Gentry classification was 0.64. All tested methods were poor predictors for functional outcome, except for the 6-location score (area under the curve: 0.71). No method was significantly better than the Gentry classification. Conclusion : The Gentry classification for TAI correlates with functional outcome, but is a poor predictor for the long-term functional outcome. None of the other tested methods was significantly better.

Published
2020
Full Text
View/download PDF

37. Communicating uncertainties when disclosing diagnostic test results for (Alzheimer's) dementia in the memory clinic: The ABIDE project.

Author

Visser LNC, Pelt SAR, Kunneman M, Bouwman FH, Claus JJ, Kalisvaart KJ, Hempenius L, de Beer MH, Roks G, Boelaarts L, Kleijer M, van der Flier WM, Smets EMA, and Hillen MA

Subjects
Aged, Ambulatory Care Facilities, Caregivers psychology, Female, Humans, Male, Middle Aged, Netherlands, Patients psychology, Qualitative Research, Alzheimer Disease diagnosis, Communication, Diagnostic Tests, Routine, Disclosure, Health Personnel statistics & numerical data, Patients statistics & numerical data, Uncertainty
Abstract

Background: The development of novel diagnostics enables increasingly earlier diagnosis of Alzheimer's disease (AD). Timely diagnosis may benefit patients by reducing their uncertainty regarding the cause of symptoms, yet does not always provide patients with the desired certainty., Objective: To examine, using both quantitative and qualitative methods, uncertainty communicated by memory clinic clinicians in post-diagnostic testing consultations with patients and their caregivers., Methods: First, we identified all uncertainty expressions of 22 clinicians in audiotaped post-diagnostic testing consultations with 78 patients. Second, we statistically explored relationships between patient/clinician characteristics and uncertainty expressions. Third, the transcribed uncertainty expressions were qualitatively analysed, determining the topic to which they pertained, their source and initiator/elicitor (clinicians/patients/caregivers)., Results: Within 57/78 (73%) consultations, clinicians expressed in total 115 uncertainties, of which 37% elicited by the patient or caregiver. No apparent relationships were found between patient/clinician characteristics and whether or not, and how often clinicians expressed uncertainty. Uncertainty expressions pertained to ten different topics, most frequently patient's diagnosis and symptom progression. Expressed uncertainty was mostly related to the unpredictability of the future and limits to available knowledge., Discussion and Conclusions: The majority of clinicians openly discussed the limits of scientific knowledge and diagnostic testing with patients and caregivers in the dementia context. Noticeably, clinicians did not discuss uncertainty in about one quarter of consultations. More evidence is needed on the beneficial and/or harmful effects on patients of discussing uncertainty with them. This knowledge can be used to support clinicians to optimally convey uncertainty and facilitate patients' uncertainty management., (© 2019 The Authors Health Expectations published by John Wiley & Sons Ltd.)

Published
2020
Full Text
View/download PDF

38. Clinicians' communication with patients receiving a MCI diagnosis: The ABIDE project.

Author

Visser LNC, van Maurik IS, Bouwman FH, Staekenborg S, Vreeswijk R, Hempenius L, de Beer MH, Roks G, Boelaarts L, Kleijer M, van der Flier WM, and Smets EMA

Subjects
Aged, Aged, 80 and over, Caregivers education, Cognitive Dysfunction etiology, Cognitive Dysfunction therapy, Female, Humans, Male, Middle Aged, Patient Care Planning, Prognosis, Qualitative Research, Surveys and Questionnaires, Cognitive Dysfunction diagnosis, Communication, Patient Education as Topic, Physician-Patient Relations, Referral and Consultation
Abstract

Background: We aimed to explore clinicians' communication, including the discussion of diagnosis, cause, prognosis and care planning, in routine post-diagnostic testing consultations with patients with Mild Cognitive Impairment (MCI)., Methods: Thematic content analysis was used to analyze audiotaped consultations in which 10 clinicians (eight neurologists and two geriatricians) from 7 memory clinics, disclosed diagnostic information to 13 MCI patients and their care partners. We assessed clinician-patient communication regarding diagnostic label, cause, prognosis and care planning to identify core findings., Results: Core findings were: clinicians 1) differed in how they informed about the MCI label; 2) tentatively addressed cause of symptoms; 3) (implicitly) steered against further biomarker testing; 4) rarely informed about the patient's risk of developing dementia; 5) often informed about the expected course of symptoms emphasizing potential symptom stabilization and/or improvement, and; 6) did not engage in a conversation on long-term (care) planning., Discussion: Clinicians' information provision about the underlying cause, prognosis and implications for long-term (care) planning in MCI could be more specific. Since most patients and care partners have a strong need to understand the patient's symptoms, and for information on the prognosis and implications for the future, clinicians' current approach may not match with those needs., Competing Interests: Leonie N.C. Visser, Ingrid S. van Maurik, Femke H. Bouwman, Salka Staekenborg, Ralph Vreeswijk, Liesbeth Hempenius, Marlijn H. de Beer, Gerwin Roks, Leo Boelaarts, Mariska Kleijer, and Ellen M.A. Smets have declared that no competing interests exist. Prof. dr. Wiesje M. van der Flier has the following competing interests: she performs contracted research for Biogen MA Inc. Her research programs have been funded by ZonMW, Health Holland, Pasman stichting, NWO, EU-FP7, EU-JPND, Alzheimer Nederland, Cardiovasculair Onderzoek Nederland, stichting Dioraphte, Gieskes-Strijbis fonds, Boehringer Ingelheim, Piramal Neuroimaging, Roche BV, Janssen Stellar, and Combinostics. All funding is paid to the institution.

Published
2020
Full Text
View/download PDF

39. Dexamethasone Therapy in Symptomatic Chronic Subdural Hematoma (DECSA-R): A Retrospective Evaluation of Initial Corticosteroid Therapy versus Primary Surgery.

Author

Miah IP, Herklots M, Roks G, Peul WC, Walchenbach R, Dammers R, Lingsma HF, den Hertog HM, Jellema K, and Van der Gaag NA

Subjects
Adult, Aged, Aged, 80 and over, Decompression, Surgical methods, Drainage methods, Female, Humans, Male, Middle Aged, Retrospective Studies, Anti-Inflammatory Agents therapeutic use, Dexamethasone therapeutic use, Hematoma, Subdural, Chronic therapy, Treatment Outcome, Trephining methods
Abstract

Worldwide, different strategies are being applied for symptomatic chronic subdural hematoma (CSDH). The aim of this study was to evaluate the efficacy of two treatment strategies for symptomatic CSDH: initial dexamethasone (DXM) therapy versus primary surgery by burr hole craniostomy (BHC). We retrospectively collected data for 120 symptomatic CSDH patients in two neurotrauma centers between 2014 and 2016, each with their own treatment protocol. Sixty patients received primary BHC (center A), and another 60 initial DXM therapy (center B). Primary outcome was evaluated by dichotomized modified Rankin Scale (mRS) score (0-3 and 4-6) and Markwalder Grading Scale (MGS) score at 3 months. Secondary outcomes were additional interventions, CSDH recurrence, mortality, complications, and duration of hospital stay. Baseline characteristics were similar in both groups. At 3 months, a favorable mRS score (0-3) was observed in 70% and 76% of patients in cohort A and B, respectively (odds ratio [OR] 0.77, 95% CI 0.30-1.98; p  = 0.59). A favorable MGS score (0-1) was observed in 96% of patients in both groups (OR 0.98, 95% CI 0.45-2.15; p  = 0.95). CSDH recurrence was 12% in cohort A and 22% in cohort B ( p  = 0.15). Mortality was 10% in both cohorts. In cohort B, additional surgery was performed in 83% at a median of 6 days, and significantly more patients had complications (55% vs. 35%, p  = 0.02), a prolonged hospitalization (10 vs. 5 days; p  = 0.02), and one or more follow-up cranial CT's (85% vs. 48%; p  < 0.001). To achieve a favorable clinical outcome, initial DXM therapy was associated with a high rate of crossover to surgery, significantly longer overall hospital stay, and more complications compared with primary surgery.

Published
2020
Full Text
View/download PDF

40. Family History is Associated with Phenotype in Dementia with Lewy Bodies.

Author

Vergouw LJM, Bosman B, van de Beek M, Salomé M, Hoogers SE, van Steenoven I, Roks G, Bonifati V, van Swieten JC, Lemstra AW, and de Jong FJ

Subjects
Age of Onset, Aged, Aged, 80 and over, Alzheimer Disease cerebrospinal fluid, Biomarkers cerebrospinal fluid, Cognitive Dysfunction, Family, Female, Humans, Kaplan-Meier Estimate, Lewy Body Disease epidemiology, Male, Middle Aged, Phenotype, Prognosis, Retrospective Studies, Survival Analysis, Lewy Body Disease diagnostic imaging
Abstract

It is currently unknown whether patients with dementia with Lewy bodies (DLB) with relatives with dementia or Parkinson's disease (familial DLB patients) have a different phenotype than sporadic DLB patients. In this study, we aimed to examine disease onset, rate of cognitive decline, survival, and Alzheimer's disease (AD) biomarkers in patients with familial DLB (n = 154) and sporadic DLB (n = 137), using linear mixed model analysis and Cox regression analysis, among others. Familial patients had a shorter survival (8.0 years) and more often elevated cerebrospinal fluid AD biomarkers (47%) than sporadic patients (9.0 years; p≤0.001; 30%, p = 0.037). Our findings suggest that genetic factors are important in DLB and that the identification of new genetic factors will probably improve the prediction of prognosis.

Published
2020
Full Text
View/download PDF

41. Clinician-patient communication during the diagnostic workup: The ABIDE project.

Author

Visser LNC, Kunneman M, Murugesu L, van Maurik I, Zwan M, Bouwman FH, Schuur J, Wind HA, Blaauw MSJ, Kragt JJ, Roks G, Boelaarts L, Schipper AC, Schooneboom N, Scheltens P, van der Flier WM, and Smets EMA

Abstract

Introduction: We aimed to describe clinician-patient communication in the diagnostic process of memory clinics, specifically clinician behavior known to facilitate knowledgeable participation of patients during consultations., Methods: In this multicenter, observational study, we audio-recorded routine diagnostic consultations of 41 clinicians and 136 patients/caregivers at eight memory clinics. Patients/caregivers completed surveys after each audiotaped consultation. We used a study-specific coding scheme to categorize communication behavior., Results: Clinicians often provided information on (results of) diagnostic testing. They infrequently invited questions and/or checked understanding. Clinician behavior to involve patients in decision-making about diagnostic testing was limited. Of note, patients/caregivers rarely expressed their information or involvement preferences. Yet, approximately, one quarter of them would have liked to receive more information., Discussion: Involving patients more explicitly by means of shared decision-making could benefit the quality of care provided in memory clinics because it enables clinicians to attune the diagnostic workup to the individual patient's needs.

Published
2019
Full Text
View/download PDF

42. The use of the PSH-AM in patients with diffuse axonal injury and autonomic dysregulation: A cohort study and review.

Author

van Eijck MM, Sprengers MOP, Oldenbeuving AW, de Vries J, Schoonman GG, and Roks G

Subjects
Adolescent, Adult, Aged, Autonomic Nervous System Diseases epidemiology, Cohort Studies, Female, Humans, Incidence, Intensive Care Units statistics & numerical data, Length of Stay statistics & numerical data, Logistic Models, Male, Middle Aged, Netherlands epidemiology, Retrospective Studies, Risk Factors, Young Adult, Autonomic Nervous System Diseases diagnosis, Autonomic Nervous System Diseases physiopathology, Diffuse Axonal Injury complications, Vital Signs physiology
Abstract

Purpose: 1) To determine the clinical expression and consequences of autonomic dysregulation in patients with diffuse axonal injury (DAI), and 2) to study the use of the "paroxysmal sympathetic hyperactivity assessment measure" (PSH-AM)., Methods: Patients clinically diagnosed with autonomic dysregulation were selected from a cohort involving 116 patients with DAI. We studied the incidence of autonomic features, treatment, and outcome. In addition a systematic review was performed., Results: Autonomic dysregulation was diagnosed in 19 of 116 (16.4%). Lower age (OR 0.95) and higher DAI grade (OR 7.2) were risk factors for autonomic dysregulation. Autonomic dysregulation was associated with an unfavourable outcome (OR 5.6) and a longer ICU and hospital stay. On the PSH-AM 57.9% (n = 11) scored a probable paroxysmal sympathetic hyperactivity (PSH), 36.8% (n = 7) scored possible, and 5.2% (n = 1) scored unlikely. The review yielded 30 articles. The incidence of autonomic dysregulation after TBI varied from 7.7-32.6% (mean 13.5%). TBI patients with autonomic dysregulation had a longer ICU stay and poorer outcome., Conclusion: Patients with DAI and autonomic dysregulation had a longer ICU stay and a poorer outcome compared to patients without autonomic dysregulation. The PSH-AM is a potential valuable tool to determine the likelihood of autonomic dysregulation., (Copyright © 2018 Elsevier Inc. All rights reserved.)

Published
2019
Full Text
View/download PDF

43. Early Predictors for Long-Term Functional Outcome After Mild Traumatic Brain Injury in Frail Elderly Patients.

Author

Abdulle AE, de Koning ME, van der Horn HJ, Scheenen ME, Roks G, Hageman G, Spikman JM, and van der Naalt J

Subjects
Aged, Anxiety epidemiology, Cohort Studies, Depression epidemiology, Dizziness epidemiology, Fatigue epidemiology, Female, Glasgow Outcome Scale, Headache epidemiology, Humans, Male, Netherlands epidemiology, Personal Satisfaction, Psychiatric Status Rating Scales, Trauma Centers, Brain Concussion epidemiology, Disability Evaluation, Frail Elderly, Recovery of Function
Abstract

Objective: To identify the effect of frailty and early postinjury measures on the long-term outcome after mild traumatic brain injury in elderly patients., Setting: Patients admitted to 3 Dutch hospitals designated as level 1 trauma centers., Participants: The elderly (≥60 years) with mild traumatic brain injury (N = 161)., Design: A prospective observational cohort study., Main Measures: Posttraumatic complaints and the Hospital Anxiety and Depression Scale determined 2 weeks postinjury; the Glasgow Outcome Scale Extended and Groningen frailty indicator determined 1 to 3 years postinjury., Results: A total of 102 nonfrail (63%) and 59 frail elderly (37%) patients, mean age of 70.8 (6.3) years were included. Most patients (54%; 72% nonfrail and 24% frail) recovered completely 1 to 3 years postinjury. Two weeks postinjury, 81% had posttraumatic complaints (83% frail and 80% nonfrail elderly), and 30% showed emotional distress (50% frail and 20% nonfrail). Frailty (odds ratio, 2.1; 95% confidence interval, 1.59-2.77) and presence of early complaints (odds ratio, 1.13; 95% confidence interval, 1.01-1.27) (Nagelkerke R = 46%) were found to predict long-term outcome, whereas age was not a significant predictor., Conclusion: The frail elderly had worse long-term outcome, and early complaints were found to be a stronger predictor of unfavorable outcome than age. Understanding the implications of frailty on outcome could help clinicians recognize patients at risk of a poor outcome and allocate care more efficiently.

Published
2018
Full Text
View/download PDF

44. Patients with Diffuse Axonal Injury Can Recover to a Favorable Long-Term Functional and Quality of Life Outcome.

Author

van Eijck M, van der Naalt J, de Jongh M, Schoonman G, Oldenbeuving A, Peluso J, de Vries J, and Roks G

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Cohort Studies, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Prognosis, Risk Factors, Young Adult, Brain Injuries, Traumatic complications, Diffuse Axonal Injury etiology, Quality of Life, Recovery of Function physiology
Abstract

Functional outcome and quality of life are difficult to predict in patients with diffuse axonal injury (DAI) after traumatic brain injury (TBI). The primary aim of this cross-sectional cohort study was to assess the long-term functional outcome in patients with DAI and to identify prognostic factors. Second, health-related quality of life (HRQL) at long-term follow-up was assessed. Patients ≥16 years of age with TBI and DAI (admitted 2008-2014) were included. Clinical and imaging data were collected. The primary outcome parameter was the Glasgow Outcome Scale Extended (GOSE) at long-term follow-up. Second, the HRQL was assessed with the Quality Of Life after Brain Injury (QOLIBRI) questionnaire. DAI was diagnosed in 185 patients. Long-term functional outcome was obtained in 134 patients (72%), median follow-up was 54 months (range 14-100); and 51% had a favorable outcome (GOSE 6-8). Independent prognostic factors were age, pupillary reaction, Hb, DAI grading, and return of consciousness ≤7 days. Sixty-two percent had a good HRQL, after a median follow-up of 57 months (range 14-100) with age as an independent prognostic factor. More than half of patients with DAI had a favorable functional outcome and a good HRQL at long-term follow-up. Also in patients with a DAI grade 3, a favorable outcome was seen. HRQL is a clinically relevant outcome measure because it reflects perceived outcome by patients. Independent prognostic variables for functional outcome were factors obtained in the acute phase after injury, whereas age was an independent prognostic factor for HRQL.

Published
2018
Full Text
View/download PDF

45. Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project.

Author

Willemse EAJ, van Maurik IS, Tijms BM, Bouwman FH, Franke A, Hubeek I, Boelaarts L, Claus JJ, Korf ESC, van Marum RJ, Roks G, Schoonenboom N, Verwey N, Zwan MD, Wahl S, van der Flier WM, and Teunissen CE

Abstract

Introduction: We compared the automated Elecsys and manual Innotest immunoassays for cerebrospinal fluid (CSF) Alzheimer's disease biomarkers in a multicenter diagnostic setting., Methods: We collected CSF samples from 137 participants in eight local memory clinics. Amyloid β(1-42) (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau) were centrally analyzed with Innotest and Elecsys assays. Concordances between methods were assessed., Results: Biomarker results strongly correlated between assays with Spearman's ρ 0.94 for Aβ42, 0.98 for t-tau, and 0.98 for p-tau. Using Gaussian mixture modeling, cohort-specific cut-points were estimated at 1092 pg/mL for Aβ42, 235 pg/mL for t-tau, and 24 pg/mL for p-tau. We found an excellent concordance of biomarker abnormality between assays of 97% for Aβ42 and 96% for both t-tau and p-tau., Discussion: The high concordances between Elecsys and Innotest in this nonacademic, multicenter cohort support the use of Elecsys for CSF Alzheimer's disease diagnostics and allow conversion of results between methods.

Published
2018
Full Text
View/download PDF

46. The Pentagon Copying Test and the Clock Drawing Test as Prognostic Markers in Dementia with Lewy Bodies.

Author

Vergouw LJM, Salomé M, Kerklaan AG, Kies C, Roks G, van den Berg E, and de Jong FJ

Subjects
Aged, Aged, 80 and over, Alzheimer Disease diagnosis, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Nursing Homes, Patient Admission statistics & numerical data, Prognosis, Retrospective Studies, Risk Factors, Lewy Body Disease diagnosis, Neuropsychological Tests
Abstract

Aims: To determine whether the pentagon copying test (PCT) and the clock drawing test (CDT) are associated with nursing home admission or survival in dementia with Lewy bodies (DLB)., Methods: The PCT and/or the CDT were retrospectively collected from 103 clinically diagnosed probable DLB patients at a university medical center and general hospital. Patients with high versus low scores on these tests were compared., Results: Kaplan-Meier analysis showed that patients with a low score on the PCT had a shorter time to nursing home admission than patients with a high score (log-rank χ2 = 6.1, p = 0.01). Patients with a low score on the PCT or the CDT had a shorter survival than patients with a high score (log-rank χ2 = 5.4, p = 0.02, and log-rank χ2 = 11.2, p < 0.001, respectively). Cox regression analyses showed the same associations with an HR of 2.2 (95% CI 1.2-4.1) for the PCT and an HR of 2.9 (95% CI 1.6-5.4) for the CDT., Conclusion: The PCT and the CDT may function as prognostic markers in DLB. This finding is clinically relevant as these tests can be applied easily in the clinical setting and can provide valuable prognostic information. Furthermore, it may improve disease management and patient selection for research purposes., (The Author(s). Published by S. Karger AG, Basel.)

Published
2018
Full Text
View/download PDF

47. Diffuse axonal injury after traumatic brain injury is a prognostic factor for functional outcome: a systematic review and meta-analysis.

Author

van Eijck MM, Schoonman GG, van der Naalt J, de Vries J, and Roks G

Subjects
Animals, Brain Injuries, Traumatic diagnostic imaging, Diffuse Axonal Injury diagnostic imaging, Humans, Magnetic Resonance Imaging, Prognosis, Brain Injuries, Traumatic complications, Diffuse Axonal Injury etiology
Abstract

Objective: To determine the prognosis of adult patients with traumatic brain injury (TBI) and diffuse axonal injury (DAI)., Methods: Online search (PubMed, Embase and Ovid Science Direct) of articles providing information about outcome in (1) patients with DAI in general, (2) DAI vs. non-DAI, (3) related to magnetic resonance imaging (MRI) classification and (4) related to lesion location/load. A reference check and quality assessment were performed., Results: A total of 32 articles were included. TBI patients with DAI had a favourable outcome in 62%. The risk of unfavourable outcome in TBI with DAI was three times higher than in TBI without DAI. Odds ratio (OR) for unfavourable outcome was 2.9 per increase of DAI grade on MRI. Lesions located in the corpus callosum were associated with an unfavourable outcome. Other specific lesion locations and lesions count showed inconsistent results regarding outcome. Lesion volume was predictive for outcome only on apparent diffusion coefficient and fluid attenuation inversion recovery MRI sequences., Conclusions: Presence of DAI on MRI in patients with TBI results in a higher chance of unfavourable outcome. With MRI grading, OR for unfavourable outcome increases threefold with every grade. Lesions in the corpus callosum in particular are associated with an unfavourable outcome.

Published
2018
Full Text
View/download PDF

48. Risk factors and outcomes associated with post-traumatic headache after mild traumatic brain injury.

Author

Yilmaz T, Roks G, de Koning M, Scheenen M, van der Horn H, Plas G, Hageman G, Schoonman G, Spikman J, and van der Naalt J

Subjects
Adult, Brain Injuries, Traumatic epidemiology, Female, Glasgow Coma Scale, Humans, Longitudinal Studies, Male, Middle Aged, Netherlands epidemiology, Post-Traumatic Headache epidemiology, Prevalence, Prospective Studies, Risk Factors, Surveys and Questionnaires, Treatment Outcome, Brain Injuries, Traumatic complications, Post-Traumatic Headache etiology, Post-Traumatic Headache psychology
Abstract

Objectives: To determine the prevalence and potential risk factors of acute and chronic post-traumatic headache (PTH) in patients with mild to moderate traumatic brain injury (TBI) in a prospective longitudinal observational multicentre study. Acute PTH (aPTH) is defined by new or worsening of pre-existing headache occurring within 7 days after trauma, whereas chronic PTH (cPTH) is defined as persisting aPTH >3 months after trauma. An additional goal was to study the impact of aPTH and cPTH in terms of return to work (RTW), anxiety and depression., Methods: This was a prospective observational study conducted between January 2013 and February 2014 in three trauma centres in the Netherlands. Patients aged 16 years and older with a GCS score of 9-15 on admission to the ED, with loss of consciousness and/or amnesia were prospectively enrolled. Follow-up questionnaires were completed at 2 weeks and 3 months after injury with the Head Injury Symptom Checklist, the Hospital Anxiety and Depression Scale and RTW scale., Results: In total, 628 patients were enrolled in the study, 469 completed the 2-week questionnaire (75%) at 2 weeks and 409 (65%) at 3 months. At 2 weeks, 238 (51%) had developed aPTH and at 3 months 95 (23%) had developed cPTH. Female gender, younger age, headache immediately at the ED and CT scan abnormalities increased the risk for aPTH. Risk factors for cPTH were female gender and headache at the ED. Patients with cPTH were less likely to have returned to work than those without cPTH (35% vs 14%, P=0.001). Patients with aPTH and cPTH more often report anxiety (20% and 28%, P=0.001) and depression (19% and 28%, P=0.001) after trauma in comparison with the group without PTH (10% anxiety and 8% depression)., Conclusions: PTH is an important health problem with a significant impact on long-term outcome of TBI patients. Several risk factors were identified, which can aid in early identification of subjects at risk for PTH., Competing Interests: Competing interests: None declared., (© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.)

Published
2017
Full Text
View/download PDF

49. Prediction of work resumption and sustainability up to 1 year after mild traumatic brain injury.

Author

de Koning ME, Scheenen ME, van der Horn HJ, Timmerman ME, Hageman G, Roks G, Spikman JM, and van der Naalt J

Subjects
Adult, Anxiety etiology, Brain Concussion complications, Cohort Studies, Depression etiology, Female, Glasgow Coma Scale, Humans, Logistic Models, Male, Middle Aged, Predictive Value of Tests, Surveys and Questionnaires, Time Factors, Brain Concussion psychology, Return to Work psychology
Abstract

Objective: To study return to work (RTW) after mild traumatic brain injury (mTBI) at several intervals after injury and to predict RTW on the basis of occupational factors in addition to demographic, personality, and injury-related factors at 6 and 12 months after injury., Methods: This was a prospective cohort study (UPFRONT study, n = 1,151) of patients with mTBI admitted to the emergency department. Patients received questionnaires at 2 weeks and 3, 6, and 12 months after injury. RTW was divided into 3 levels: complete (cRTW), partial (pRTW), and no RTW., Results: Rates of cRTW increased from 34% at 2 weeks to 77% at 12 months after injury, pRTW varied from 8% to 16% throughout the year. Logistic regression (complete vs incomplete RTW) demonstrated that apart from previously identified predictors such as demographics (e.g., age and education) and injury characteristics (e.g., cause and severity of injury) and indicators of psychological distress, occupational factors were of influence on work resumption after 6 months (area under the curve [AUC] = 0.82), At 12 months, however, the model was based solely on the presence of extracranial injuries and indicators of maladaptation after injury (AUC = 0.81)., Conclusions: RTW after mTBI is a gradual process, with varying levels of RTW throughout the first year after injury. Different predictors were relevant for short- vs long-term work resumption, with occupational factors influencing short-term RTW. However, for both short- and long-term RTW, posttraumatic complaints and signs of psychological distress early after injury were relevant predictors, allowing early identification of patients at risk for problematic work resumption., (© 2017 American Academy of Neurology.)

Published
2017
Full Text
View/download PDF

50. Prospective Evaluation of Noninvasive HeadSense Intracranial Pressure Monitor in Traumatic Brain Injury Patients Undergoing Invasive Intracranial Pressure Monitoring.

Author

Herklots MW, Moudrous W, Oldenbeuving A, Roks G, Mourtzoukos S, Schoonman GG, and Ganslandt O

Subjects
Adult, Aged, Brain Injuries, Traumatic complications, Cerebral Hemorrhage, Traumatic etiology, Cerebral Hemorrhage, Traumatic physiopathology, Equipment Design, Female, Humans, Intracranial Hypertension diagnosis, Intracranial Hypertension etiology, Intracranial Hypertension physiopathology, Male, Middle Aged, Monitoring, Physiologic instrumentation, Prospective Studies, Subarachnoid Hemorrhage, Traumatic etiology, Subarachnoid Hemorrhage, Traumatic physiopathology, Young Adult, Brain Injuries, Traumatic physiopathology, Intracranial Pressure physiology
Abstract

Background: Currently, intracranial pressure (ICP) is measured by invasive methods with a significant risk of infectious and hemorrhagic complications. Because of these high risks, there is a need for a noninvasive ICP (nICP) monitor with an accuracy similar to that of an invasive ICP (iICP) monitor., Objective: We sought to assess prospectively the accuracy and precision of an nICP monitor compared with iICP measurement in severe traumatic brain injury (TBI) patients., Methods: Participants were ICP-monitored patients who had sustained TBI. In parallel with the standard invasive ICP measurements, nICP was measured by the HeadSense HS-1000, which is based on sound propagation. The device generated an acoustic signal using a small transmitter, placed in the patient's ear, and picked up by an acoustic sensor placed in the other ear. The signal is then analyzed using proprietary algorithms, and the ICP value is calculated in millimeter of mercury (mm Hg)., Results: Analysis of 2911 paired iICP and nICP measurements from 14 severe TBI patients showed a good accuracy of the nICP monitor indicated by a mean difference of 0.5 mm Hg. The precision was also good with a standard deviation of 3.9 mm Hg. The Pearson r correlation was 0.604 (P < 0.001)., Conclusions: The HeadSense HS-1000 nICP monitor seems sufficiently accurate to measure the ICP in severe TBI patients, is patient friendly, and has minimal risk of complications., (Copyright © 2017 Elsevier Inc. All rights reserved.)

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results